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EPIGRAPH 
 
 
 
 
Feeling my way through the darkness, 
Guided by a beating heart. 
I can't tell where the journey will end 
But I know where to start. 
 
— Avicii, Wake Me Up 
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Atrial fibrillation (AF) is the most prevalence form of arrhythmia, affecting around 
3% of the general population. The mechanism and disease-causing factor of AF are 
remaining unclear. Thus, the establishment of a high-throughput phenotypical screening 
platform could advance the understanding of AF and identify novel cardiac rhythm 
regulators that could inform future anti-arrhythmic development.   
  xviii 
AF is an atrial-specific arrhythmia. Thus, to specify the screening target space, 
human pluripotent stem cell-derived atrial like cardiomyocytes (ACM) is required. To 
effectively generate large scales of ACM, the regulatory network and differentiation 
protocol of cardiac mesoderm progenitor (CMP) has to be established. We performed 
genome-wide microarray and identified Id1 is required and sufficient to direct the 
differentiation of CMP from pluripotent cells both in mouse and human. Moreover, in vivo 
data have shown the essential role of Id gene family during mammalian early heart tube 
formation. Retinoic acid (RA) was applied as the atrial-specific cue for the differentiation 
of ACM from CMP. The resulting ACMs were molecularly validated. The qPCR, 
immunofluorescence, and RNA-seq results demonstrated atrial-specific genes were highly 
expressed in the ACM compared to non-RA-treated ventricular-like cardiomyocyte 
(VCM). Functional validation including action potential, calcium transient, and 
contractility also confirmed the atrial-like physiology behavior of ACM. 
To efficiently screen through the genome to identify potential arrhythmia-causing 
genes, a fully automated single-cell and high-throughput phenotypical platform was 
established. The platform record and analyze action potential traces from each cell within 
the field of view with image processing software and algorithm. Physiological metrics were 
then retrieved. Action potential duration at 75% of repolarization (APD75) and arrhythmia 
index (AI) were calculated as metrics to determine the degree of arrhythmia-like activity 
induced by the treatment. To further validate the platform, siRNA against 20 previously 
shown AF-associated genes identified through rare variants and genome-wide association 
study (GWAS) were transfected to ACM. The down-regulation of some of the genes in the 
list induced the prolongation or shortening of action potential duration (APD), but not 
  xix 
sufficient to trigger the arrhythmia-like activity. AF-associated perturbagens such as β-
adrenergic agonists/antagonist, and tissue fibrosis, mimicking by co-culturing fibroblasts 
with ACM also induced electrical remodeling but not arrhythmia-like activity. However, 
by applying perturbagens along with siRNA against AF-associated genes that had the most 
severe phenotype triggered dramatic arrhythmia-like behavior. Moreover, distinct 
combinations of siRNA against AF-associated gene with perturbagens induced different 
arrhythmia-like-phenotypes. 
The overall result indicated the complexity of the disease mechanisms as well as 
the unmet need to identify novel cardiac rhythm regulators and potential AF-causing genes. 
The ACM differentiation protocol and the high-throughput phenotypical screening 
platform could further advance the understanding of AF and catalyze the discovery of 
antiarrhythmics.  
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Chapter 1  
 
Introduction 
 
 
 
 
 Atrial fibrillation is the most common cardiac arrhythmia affecting more than 33 
million individuals world wild that can cause detrimental complications such as stroke, heart 
failure, and death. Current treatments of AF are surgical ablation and the prescription of 
antiarrhythmics. Surgical ablation is an invasive and sophisticated technique and might 
require several ablations to eliminate the ectopic firing loci. On the other hand, anti-atrial 
fibrillation drugs have relatively low efficacy and a considerable high off-target effect that 
could increase the risks, especially pro-arrhythmia, highlighting the needs to develop novel 
anti-arrhythmic treatments. The elucidation of underlying molecular determinants and the 
identification of novel AF-causing genes are the primary goals. 
 With the advance of sequencing technology and CRISPR-Cas gene-editing 
technique, genetic researches on familial AF and GWAS disclosed several AF-related 
genes. Despite the effort, the molecular basis of the majority of AF patients is still poorly 
understood. Two common techniques to model cardiomyocyte physiology are the whole-
cell patch-clamp electrophysiology and optical recording-based system. The patch-clamp 
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method is able to record major currents of cardiomyocyte during the excitation-contraction 
coupling through carefully monitored current amplitude. However, one of the constraints of 
the patch-clamp method is the limited throughput that is insufficient for large-scale screens. 
The optical recording-based system utilizes fluorescent dyes such as voltage-sensing dyes 
or calcium-sensing dyes to visualize cardiomyocyte physiology responses. Image analysis 
and physiological parameter calculation are then conducted using recorded whole-well 
images. Although the automated workflow provides tremendous throughput, the limitation 
of the system is the resolution of physiology metrics due to the whole-well averaged 
fluorescent signal analysis. Thus, establishing a platform that combines the automated high-
throughput physiology system with the single-cell level resolution to rapidly generate 
physiological measurements of   CM could substantially advance the understanding of 
molecular basis of AF and the discovery of new anti-AF drugs. 
 This thesis summarizes the effort that has been made for establishing a physiology 
screening platform to elucidate novel AF-causing candidates. The contributions comprise 
three main significances: (1) The generation of Id1-derived CMP and ACM. (2) The 
establishment of the single-cell and high-throughput CM functional analysis platform. (3) 
The modeling of arrhythmia-like activity in ACM with misregulation of known AF-causing 
genes and AF-related perturbagens. The main text of this thesis is organized along the 
following thematic lines. 
 Chapter 2 describes an original Id1-induced CMP differentiation protocol. Id1, 
identified through genome-wide microarray, is required and sufficient to promote 
mesoderm formation. The resulting Id1-induced CMP is highly cardiogenic. Moreover, the 
in vivo data demonstrated the Id family is essential for mammalian early heart tube 
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formation. 
 Chapter 3 addresses CM subtype-specific differentiation and the validation of the 
resulting ACM and VCM. VCM were derived from spontaneous differentiation, and ACM 
were generated by the administration of atrial-specific differentiation cue, retinoic acid. The 
identity of resulting CM subtypes was comprehensively validated in both molecular 
signature and functional assessment aspects. 
 Chapter 4 exhibits an automated single-cell and high-throughput functional 
screening platform. Based on optical recording system, the platform utilized custom built 
image processing software and trace analysis algorithm to generate the single-cell resolution 
of CM physiology.  
 Chapter 5 validates the platform with a list of previously known AF-associated 
genes. siRNAs against these genes were transfected into ACM and physiology parameters 
were retrieved through the platform. The result showed that the down-regulation of several 
of these genes induced electrical remodeling but not sufficient to induced arrhythmia-like 
activity. Only with the presence of common AF-associated perturbagens, knocking down 
the genes triggers arrhythmia-like activity. Moreover, different combinations of siRNA and 
perturbagens induced distinct arrhythmia phenotypes. 
 Chapter 6 summarizes the contributions of this dissertation and discusses three 
possible future research directions.
  4 
Chapter 2  
 
Identification of Id Family as 
Multipotent Mesoderm Progenitor 
Regulator 
 
 
 
 
2.1 Background 
The ability to produce unlimited amounts of cardiomyocytes in the laboratory is the 
pre-requisite of being able to study and conduct large-scale screenings on cardiac diseases. 
In the late 2000s, when researchers begin to harness the power of human pluripotent stem 
cells (hPSCs), there was no efficient cardiomyocyte differentiation protocol. Serum-based 
protocols often provide unstable and poor cardiomyocyte yields. Therefore, there is an 
unmet need to establish a differentiation protocol that could robustly and efficiently 
generate massive amounts of cardiac progenitors and subsequent cardiomyocytes for 
cardiac disease studies.  
Heart formation begins during the early gastrulation when the specification of the 
three distinct germ layers, ectoderm, endoderm, and mesoderm, undergo migration and 
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forming cardiac primordium consist of CMPs. The progenitors then move ventrally and 
compose the linear heart tube that undergoes cardiac looping and further assembles into a 
fully functional heart. The spatiotemporal activation and inhibition of various signaling 
pathways orchestrate the allocation of the germ layers and the formation and patterning of 
the organs. Studies of developmental biology over the past two decades have established 
the mechanisms of how mesoderm was induced through the activation of extracellular 
signals, such as Activin/Nodal and bone morphogenic proteins (BMPs) signaling pathways. 
However, the understanding of the down-stream intracellular mediators controlling this 
process has never been adequately explained. Understanding the regulatory network of 
mesoderm formation could further advance the design of mesoderm and cardiac 
differentiation protocol, and gain insights into the development and regenerative aspects of 
the heart. 
 
2.2 Results 
2.2.1 Identification of Regulators of Cardiac Mesoderm Progenitor Formation 
Previous studies have illustrated the mechanism of cardiac specification is initiated 
through the activation of transcription factors Eomes, Mesp1, and Mesp2, which then 
further activate series of cardiac-specific transcription factors (Gata4, Nkx2-5, Hand2, and 
Myocd) and repress pluripotency genes (Oct4, Nanog, and Sox2) as well as endoderm 
effectors (Foxa2, Sox17) [1, 2]. Furthermore, attenuating Activin/Nodal signaling via the 
blockade of activin receptor Acvr1b directs the differentiation mesendoderm towards 
mesoderm progenitor [3]. Thus, we hypothesize that the down-stream regulators in 
  6 
response to the inhibition of activin signaling play a critical role during the differentiation 
of CMP [Figure 2.1A]. 
Mouse embryonic stem cells (mESCs) reaches the mesendoderm stage (Gsc+, 
Fox2+, and T+) at day 3 after the initiation of differentiation with Activin/Nodal signaling. 
Mesendoderm progenitors then further differentiate into either endoderm progenitors 
(Foxa2+) or CMPs (Kdr+, Meps1+, Cdh11+, Snai1+). The attenuation of Acvr1b directs 
mesendoderm progenitors towards CMPs very efficiently [Figure 2.1B–C]. To elucidate 
the downstream effectors of cardiogenic mesoderm formation, we performed mRNA 
microarray to evaluate the differential expressions of the mRNA during the process [Figure 
Figure 2.1 Identification of mesoderm effectors. (A) Schematic diagram of CMP differentiation protocol. 
(B–C) IF of resulting day 6 cells. (D) Microarray to identify genes up-regulated in response to siAcvr1b. (E) 
14 qPCR validated mesoderm effector gene candidates. 
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2.1D]. We identified 33 genes were up-regulated in response to siRNA against Acvr1b 
relative to the scrambled sequence of siRNA, and of which 14 were further confirmed by 
quantitative PCR (qPCR) [Figure 2.1E]. In the list of 14 candidate genes, eight of them are 
involved in the regulation of gene transcription, including transcription factors (Evx1, 
Gbx2, Irx3, Irx5, and Sox9), helix-loop-helix (HLH) protein that forms heterodimers with 
basic HLH family of transcription factors (Id1 and Id3), and DNA repair mediator 
(Gadd45g). Three of the candidates involved regulation of signaling pathway (Fgfbp3, 
Crabp2, and Cxcl12), two are related with RNA binding and regulation (Elavl3 and Tnrc6a), 
and one with possible centrosome-associated function (Grrp1). 
 
2.2.2 Id1 is Required and Sufficient to Direct the Formation of Cardiac Mesoderm 
Progenitor in mESC and hESC 
To further assessed the role of the 14 candidate genes during mesoderm 
differentiation, we transfected mESCs on day 3 with siAcvr1b along with siRNA against 
all 14 candidate genes individually. Of all the candidate genes, only siRNAs against Grrp1, 
Evx1, and Id1 substantially decrease the number of Kdr+ mesoderm cells in the expense of 
the increasing population of Fox2+ endoderm cells along with the down-regulation of 
mesoderm markers including Mesp1, Snai1, and Cdh11[Figure 2.2A–E]. These results 
indicate that Grrp1, Evx1, and Id1 is required during the process of mesoderm formation. 
We then examined the sufficiency of these remaining three candidate genes during the 
differentiation by the overexpressing system with lentivirus. We first generated mESC 
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lines overexpressing all seven possible combinations of Grrp1, Evx1, and Id1 [Figure 2.2F]. 
These mESC lines were than differentiate into mesendoderm and further evaluate the 
mesoderm formation efficiency without the blockade of Acvr1b. Surprisingly, Id1 along 
without attenuating Acvr1b signaling was sufficient to significantly induce more than 22-
fold of Kdr+ mesoderm cell formation over parental control mESC [Figure 2.2G–I]. 
Figure 2.2 Id1 is required and sufficient to promote CMP formation. (A-D) 3 genes are required during 
mesoderm differentiation. (E) Down-regulation of the 3 genes reduce mesoderm marker expression. (F) All 
possible combination of overexpression of 3 genes were examined. (G–I) qPCR and IF result indicates the 
overexpression of Id1 is sufficient to promote mesoderm formation. 
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We then investigate whether the role of Id1 during mesoderm progenitor 
differentiation is evolutionarily conserved in human embryonic stem cells (hESCs). 
Consistent with the result in mESC, flow cytometry data indicates Id1 drastically increase 
the population of Kdr+ mesoderm cells during the mesoderm-endoderm specification in 
hESC system [Figure 2.3A–D]. Moreover, the temporal mRNA expression results of Id1-
induced Kdr+/KDR+ mesoderm progenitor (iMPs) showed Id1 overexpression not only 
promotes known mesoderm regulators Mesp1/MESP1 and Kdr/KDR, as well as the early 
upregulation of Exv1/EVX1 and Grrp1/GRRP1 [Figure 2.3E–L]. Collectively, these data 
Figure 2.3 Id1 overexpression induced mesoderm mechanism is conserved in human. (A–D) Overexpression 
of Id1 increase Kdr+ cell percentage. (E–H) Mouse mesoderm marker expression pattern. (I–L) Human 
mesoderm marker expression pattern.  
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show that Id1 act as an evolutionarily conserved initiator of mesoderm differentiation 
program and plays a central role within the regulatory network in both mESC and hESC. 
To examine the multipotency and the cardiogenic character of the iMPs, cells were 
first produced until day 6 of differentiation for mouse and day 5 for human. At this point, 
iMPs could be cryopreserved or used fresh. On day 15 of spontaneous differentiation under 
basal media without cytokines, we performed qPCR on markers of various mesoderm 
lineage ordinarily present in the heart, including cardiomyocyte (Myh6, Tnnt2, and Actc1), 
vascular endothelial cells (Pecam1 and Cadh5), smooth muscle cells (Myh11), and 
Figure 2.4 The multipotency of CMP. (A) qPCR result of mESC-derived CMP on markers of mesoderm 
lineages. (B) qPCR result of hESC-derived CMP on markers of mesoderm lineages. (C–D) IF and 
quantification result of day 15 hESC-derived CMP. (E) Schematic diagram of the multipotency of CMP. 
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fibroblasts (Postn and Tagln) as well as immunofluorescence staining [Figure 2.4A–B]. 
Both mouse and human iMPs were able to give rise to multiple lineages, and most 
importantly, the vast majority of the cells derived from iMPs were ACTC1+ 
cardiomyocytes [Figure 2.4C–E]. 
In addition to identifying the cardiogenic aspect of these iMPs, we further 
investigate the function of the iMP-derived cardiomyocytes which includes the rhythmical 
contraction behavior, electrical excitability, calcium-induce calcium release (CICR) 
mechanism, and response to hormonal stimuli. High-speed microscopic kinetic imaging 
revealed the rhythmical contraction activities of day 15 iMP-derived cardiomyocytes 
[Supplement 2.1]. By labeling cells with voltage-sensing probes or fluorescent calcium 
indicator, we observe periodic action potential activities and CICR cycles [Figure 2.5A–
D]. Additionally, these cardiomyocytes showed increase beat rate in response to β-
adrenergic agonist Isoproterenol [Figure 2.5E–F]. In summary, we have identified a novel 
pathway to generate multipotent CMPs that spontaneously differentiate into functional 
cardiomyocyte efficiently. 
Figure 2.5 Functional assessment of resulting CM. (A) Schematic diagram of functional assessment 
protocols. (B–C) Calcium-sensing probe recording and calcium transient trace. (D) Action potential trace in 
the baseline condition. (E) Action potential trace of CM abruptly treated with isoproterenol (100 nM) (F) 
Quantification result on the average beat rate of baseline and isoproterenol-treated CM.  
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2.2.3 Id1 Promotes Cardiac Mesoderm Differentiation by Binding and Inhibiting 
Tcf3 and Foxa2 
As a family member of HLH protein, Id1 regulate gene expressions through 
forming heterodimers with basic-helix-loop-helix (bHLH) transcription factors rather than 
directly binds with the DNA [4]. The canonical binding targets are class I bHLH 
transcription factors, also known as E proteins, Tcf3, Tcf4, and Tcf12 [4-6]. To elucidate 
the regulatory network during mesoderm differentiation, we examined whether the down-
regulation of E proteins with siRNA individually or in combinations were able to 
phenocopy the result of Id1 overexpression promoting Kdr+ mesoderm progenitor 
formation in mESCs during the mesoderm specification process. All combinations promote 
mesoderm formation and interestingly, the combinations that contain siTcf3 have a better 
yield of CMP compares to other combinations without siTcf3 [Figure 2.6A–C]. The 
inhibition of Tcf3 through heterodimerization with Id1 plays a crucial role in mesoderm 
specification. Although studies implicated Tcf3 as a direct binding target of Id1, the down-
regulation of Tcf3 could only partially phenocopy the result of inducing mesoderm 
formation through siAcvr1b or Id1 overexpression. 
To further identify additional roles of how Id1 mediates mesoderm induction, we 
hypothesized Id1 might promote mesoderm formation through down-regulating the 
repressors of cardiogenic mesoderm formation. Thus, genes identified in microarray that 
were down-regulated in response to siAcvr1b at day 4 mesoderm differentiation could be 
potential cardiogenic mesoderm repressors regulated by Id1. We identified 53 gene 
candidates, and 17 were validated through qPCR [Figure 2.6D]. We then verified whether 
down-regulating any of these 17 genes through siRNA would be sufficient to induce MCP 
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formation. Out of these 17 genes, only the knock-down of Foxa2 was sufficient to promote 
Kdr+ mesoderm progenitor formation without the attenuation of Acvr1b signal [Figure 
2.6E–F]. Although no reports have shown that Id1 has direct interaction with forkhead 
Figure 2.6 Id1 promote mesoderm formation mainly by inhibiting endoderm genes Tcf3 and Foxa2. (A) 
Down-regulation of canonical binding partner Tcf3 promotes mesoderm formation. (B–C) IF result of down-
regulation Tcf3 promotes mesoderm formation. (D–F) Identification of Foxa2 as an inhibitor of mesoderm 
differentiation. (G) qPCR result shows Id1 inhibits Foxa2 expression level. (H–I) Downregulation of Tcf3 
and Foxa2 increase mesoderm marker expression. (J) IF result shows the downregulation of Tcf3 and Foxa2 
partially recapitulate Id1 overexpression phenotype. 
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transcription factors, in the constitutively Id1-overexpressing mESC, the expression level 
of Foxa2 was strongly decreased on day 4 of differentiation, indicating that Id1 may 
indirectly inhibit the expression of Foxa2. [Figure 2.6G]. 
As predicted, Kdr+ mesoderm progenitor induced by Tcf3 and FoxA2 knock-down 
expressed a prominent level of mesoderm markers (Mesp1, Snai1, Cdh11), and co-
transfection of siRNA against Tcf3 and FoxA2 further enhances the differentiation of 
cardiogenic mesoderm [Figure 2.6H–J]. Taken together, these results clarify the regulatory 
network of Id1 promoting MCP formation partially through forming heterodimers with 
canonical binding target Tcf3 and repressing the antagonist of mesoderm formation Foxa2. 
 
2.2.4 Id genes are essential for early heart development in vivo in mammalian 
To further identify the role of Id gene family in vivo during heart development, first, 
we used Xenopus embryo as our validation platform. Since Xid2 is the closest ortholog to 
mouse Id1 (with amino acid sequence 79% identical and 93% positive), we performed 
equatorial and hemilateral injection of Xid2 mRNA directly to the embryo [Figure 2.7A–
B]. Xid2 injection caused a dramatic expansion of mesoderm tissue, stained with Xbra and 
Xmespb in gastrula stage embryos [Figure 2.7C–F]. Next, to examine the underlying 
mesoderm has cardiogenic differentiation ability, Xnkx2-5 expression was assessed at the 
tailbud stage (stage 25). Remarkably, the overexpression of Xid2 massively induced the 
expression area of Xnkx2-5, and conversely, the area marked by skeletal muscle marker 
Xmlc remained unchanged [Figure 2.7G–I]. Collectively, these data show that the 
mechanism of Xid2 in Xenopus embryos, ortholog to mouse Id1 in the mESC, has an 
evolutionarily conserved function of promoting the formation of cardiogenic mesoderm. 
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The gain-of-function experiment shows that Id proteins are sufficient to direct the 
formation of cardiogenic mesoderm in vitro (mESC and hESC) and in vivo (Xenopus 
embryo). We then further explore the requirement of Id protein during mesoderm 
differentiation. Total four members, Id1, 2, 4 and 4, are there in the family, and previous 
studies have performed triple-knockout (Id1, 2, and 3) in mouse and observed complex 
cardiac defects but did not completely ablate the heart [7]. We hypothesized that there are 
functional redundancy or compensatory activity between the Id family members. To further 
test the hypothesis, we performed whole Id family quadruple-knockout using CRISPR-
Cas9 genome editing strategy in mouse embryos. To enhance the knockout efficiency, we 
designed single-stranded RNA guide against both the start codon (ATG) and the beginning 
Figure 2.7 In vivo validation of Id genes gain of function. (A) Schematic diagram of injecting Xid2 into 
xenopus embryo. (B) Xid2 and Id1 sequence alignment. (C–F) Injection of Xid2 on only one side of the 
embryo enlarges mesoderm tissue. (G–I) Enlarged mesoderm tissue further differentiated into cardiac 
progenitors in later stage. 
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of HLH binding domain [Figure 2.8A]. Guide RNAs and Cas9 were injected into mouse 
zygotes and reimplanted back to a female surrogate mouse. Embryos were then harvested 
at various stages. In situ hybridization of the early cardiac precursors (Smarcd3 and Tbx5), 
and cardiac marker (Nkx2-5) were evaluated throughout the wild-type and Id1-4 mutants. 
Remarkably, the most anterior region of the cardiac crescent was missing in the Id1-4 
Figure 2.8 Id genes are essential during mammalian early heart formation. (A) Schematic diagram of 
generating Id genes mutant with CRISPR-Cas9 gene-editing tool. (B-U) In situ hybridization results from the 
most severe Id1–4 mutants—compared with wild type (individual mutants are marked by #) and plus one 
less-affected mutant (O); analysis of Smarcd3 at E7.75 (B-E), Tbx5 at E8.0 (F–I), Nkx2.5 at E8.25 (J–M; 
plus transverse sections through the heart tube-forming region [K′,M′]), Nkx2.5 at E8.5 (N–Q), and Tbx5 at 
E8.5 (R–U). (Yellow arrowheads) Missing heart tube (or missing heart tube-forming region at cardiac 
crescent stages) in Id1–4 mutants; (white arrowhead) malformed heart tube; (black arrows) the plane of 
transverse sectioning through the heart tube-forming region; (white dash lines) posterior–lateral cardiac 
regions. 
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mutant embryo stained with Smarcd3 and Tbx5 at E7.75 and E8.0 respectively. The two 
lateral domains in the posterior of the heart tube formation region remained in the mutant 
embryo suggested that mesoderm was only partially ablated and the remaining CMPs were 
able to migrate to the proper region [Figure 2.8B–M]. Histological sections demonstrated 
the absence of anatomical heart tube formation and failure of the foregut closure [Figure 
2.8K’–M’]. Moreover, at a slightly later time point, E8.25 and E8.5, due to the absence of 
the anterior region of the cardiac crescent, the embryo failed to form heart tube that 
normally looped at the time [Figure 2.8N–U].  In summary, the heart tubes were ablated in 
the whole-family Id1-4 knockout embryos indicate the requirement of Id family during in 
vivo cardiogenic mesoderm formation. 
 
2.3 Discussion 
2.3.1 Id Genes Orchestrated the Cardiogenic Mesoderm Differentiation in vitro, in 
vivo, and across Different Species 
Activin/Nodal signaling thresholds dictate the cell fate decision of whether 
mesendoderm differentiates toward mesoderm or endoderm. High levels of activin have 
been shown favoring endoderm formation across different biological systems including 
mESC, hESC, zebrafish, Xenopus, and mice [8-11]. Through the blockade of Acvr1b 
signaling, we identified Id proteins in the downstream acts as a potent mesoderm agonist 
by up-regulating Evx1 and Grrp1, which are shown required during the mesoderm 
differentiation process, as well as repressing the antagonists of mesoderm formation, Foxa2 
and Tcf3 [Figure 2.9]. The pro-mesoderm function of Id proteins can override the signaling 
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pathways of high concentration of Activin that leads to the endoderm program, indicating 
the molecular mechanism of Id proteins act in the down-stream of Activin signaling 
pathway. Consistent to our finding, studies have shown BMP signaling directly activates 
Figure 2.9 Id genes orchestrate cardiogenic mesoderm differentiation in vertebrates. Id genes control the 
activation of the cardiogenic mesoderm differentiation program in mesendoderm progenitors by inhibiting 
the activity of repressors (Tcf3 and Foxa2) while promoting the expression of activators of cardiogenic 
mesoderm differentiation (Evx1, Grrp1, and Mesp1). The Id-controlled network induces cardiogenic 
mesoderm (Mesp1 and Kdr) differentiation from pluripotent cells. Id1-induced CMPs generated from 
pluripotent stem cells are cryopreservable and spontaneously form contracting cardiomyocytes as well as 
vascular endothelial cells,,smooth muscle, and fibroblasts. 
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the transcription of Id protein [12-15] and BMP signaling pathways have been known for 
inducing mesoderm progenitor by negatively regulates endoderm induction in mouse and 
Xenopus [16, 17]. Additionally, the blockade of BMP singling completely abolished 
mesoderm formation [11]. In conclusion, Id proteins act as a dominant molecular cue of 
mesoderm induction and play a central role in the evolutionary conserved regulatory 
network of the formation of CMP [Figure 2.9]. 
 
2.3.2 Id genes are required for cardiac progenitor that forms heart tube during 
cardiac development 
Mesp1 is the earliest known marker of cardiac progenitor [18, 19], and the 
overexpression of Mesp1 promotes the specification of cardiac progenitors [20]. In our 
study, Mesp1 temporal expression data shows that the overexpressing Id1 in both mESCs 
and hESCs promotes the level of Mesp1/MESP1. Additionally, the direct injection of Xid2 
mRNA in Xenopus embryo confirms the enlargement of Xmespb+ tissue area, which both 
suggest Id proteins expressed precedes and up-regulates Mesp1 [Figure 2.7E–F]. However, 
the cardiac progenitor population (Nkx2-5+ and Tbx5+) is not entirely ablated in CRISPR-
Cas9 induced Id1-4 knockout mouse embryos. The small fraction of lateral domains on 
both sides of the mesoderm posterior to the heart tube-forming region suggesting that these 
cardiac progenitors may have different origins than Id proteins-induced cardia progenitors 
[Figure 2.8H–I, L–M, P–Q, T–U]. 
Mammalian heart arises from a series complex morphogenetic process via cardiac 
progenitor originated distinctly, the first and second heart fields (FHF and SHF). The FHF 
give rise to the left ventricle and part of the atria and the SHF to the right ventricle, outflow 
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tract and part of the atria [21]. Colonel and molecular lineage tracing analysis of Mesp1-
expressing cells within the cardiac tissue demonstrated that Mesp1 marks distinct classes 
of cardiac progenitors with limited lineage differentiation ability during gastrulation. Early 
(E6.5) and more anterior Mesp1+ mesoderm progenitors first give rise to the FHF, whereas 
late (E7.5) and more posterior Mesp1+ mesoderm progenitors to SHF [22]. Together, these 
observations suggest that cardiomyocytes arise from the early Mesp1 activation, due to the 
induction of Id proteins, contribute to the FHF derivatives. Additionally, RNA expression 
data show that Id1-induced cardiomyocytes express high levels of FHF markers (HCN4 
and TBX5) and down-regulated SHF markers (ISL1 and SIX2) during cardiac 
differentiation. Thus, these findings suggest that there are at least two different distinct 
populations of CMPs, Id-dependent and Id-independent, which very likely to give rise to 
FHF and SHF respectively. 
 
2.3.3 Id1-induced Cardiac Mesoderm Progenitors as a novel, robust, and efficient 
way of generating Cardiomyocytes 
In this study, we show the importance of the role of Id protein during cardiogenic 
mesoderm differentiation as well as the evolutionarily conserved mechanisms across 
different species and systems, including mESCs, hESCs, hPSCs (data not shown), 
Xenopus, and mouse. The cardiac-centric, single-factored Id proteins signaling 
transduction allowed us to have simple, robust, and tight controls over cardiac 
differentiation. Also, the ability to cryopreserve MCPs and uncouple cardiogenic 
progenitor generation from subsequent cardiomyocyte differentiation production allows us 
to bank, validate, and access to different batches easily. Furthermore, the resulting 
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cardiomyocytes were functionally validated which displayed rhythmic action potential and 
calcium handling, as well as being able to respond to hormonal stimuli. The average 
cardiomyocyte differentiation efficiency (percentage of ACTC1+ cells over DAPI+ cells) is 
around 85%. Also, the simple protocol could easily be scaled up into the 15-cm petri dish 
format that generates a large number of cardiomyocytes (>108 per batch). Taken these 
features together, Id1-induced CMP is a promising new protocol for varies applications, 
including deciphering gene networks regulating heart development and studying 
fundamental mechanisms controlling cardiomyocyte physiology. The resulting 
cardiomyocytes have the potential for transplanting and abilities to regenerate in patients 
after heart injuries and myocardial infarction. Lastly, generating hESC or hPSC-derived 
cardiomyocytes efficiently provides the field materials for patient-specific cardiac disease 
modeling and high-throughput screenings to identify disease mechanisms and drug 
discovery. 
 
2.4 Conclusion 
This study presents Id genes are crucial regulators during mesoderm differentiation. 
Through the microarray screening, we have identified Id1 is required and sufficient to 
promote mesoderm cardiac mesoderm formation. Moreover, the result shown Id1 induces 
mesoderm by up-regulating downstream mesoderm genes, including Kdr and Mesp1, as 
well as inhibiting the functions of endoderm genes, such as FoxA2. The resulting Id1-
induced CMP could differentiate into CM efficiently. Furthermore, the in vivo gain of 
function result indicates the enlarged cardiac mesoderm progenitor region could later give 
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rise to cardiac tissue. The CRISPR-Cas mediated loss of function demonstrated the 
essential role of Id genes during mammalian early heart formation. 
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Chapter 3  
 
The Establishment of Id1-induced 
hPSC-derived Ventricular-like and 
Atrial-like Cardiomyocytes 
 
 
 
 
3.1 Background 
The generation of a significant amount of functional human pluripotent stem cell-
derived cardiomyocytes (hPSC-CM) of defined heart field origin is a prerequisite for 
studying cardiac diseases in large-scale screenings, disease modeling, and cell-based 
regenerative therapies. The mammalian heart is originated from the first and second heart 
field (FHF and SHF) that further developed into a four-chambered organ. Atriums served 
as reservoirs for receiving and delivering blood from the systemic and pulmonary veins, 
and ventricles expel blood back to the lungs and body. Given the fact of diverse 
physiological properties and distinct development origins, studies have shown major 
differences between atrial and ventricular cardiomyocyte in multiple aspects including cell 
morphology, gene and protein expression landscape, and electrophysiology [23, 24]. 
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Additionally, the intrinsic differences between the subtypes also contribute to distinct 
chamber-specific cardiomyopathies. For instance, hypoplastic left heart syndrome or 
arrhythmogenic right ventricular dysplasia occurs only in the ventricles, whereas atrial 
fibrillation takes place in the atriums [25-27]. Current chamber-specific disease studies and 
preclinical screening assays are mainly performed using non-cardiac recombinant cell lines 
expressing non-native cardiac genes, mixed population culture of cardiomyocyte subtypes, 
or non-primate animal models. However, these models may not accurately reflect as a 
physiologically relevant biological system. To overcome the limitations, a highly efficient 
subtype-specific hPSC-CM differentiation technique is required for the study and 
development of novel therapies and disease modeling in a subtype-specific manner. 
 
3.2 Results 
3.2.1 Retinoic Acid Promotes Atrial Specification During Cardiomyocyte 
Differentiation 
Several studies have described efficient cardiomyocyte differentiation protocols 
[28-34]. However, none have discussed the heart field origin of the resulting 
cardiomyocytes. Retrospective lineage analysis and genetic tracing have shown two 
distinct populations of cardiac progenitors contribute the FHF and SHF during heart 
development in varies vertebrate systems, where FHF progenitors would than give rise to 
the left ventricle and part of atriums [35-38]. Furthermore, several studies have reported 
RA signaling drives mesodermal progenitors toward an atrial fate in mouse, rat, hESC, and 
hPSC system, indicating the mechanism of RA inducing atrial cardiomyocyte is essential 
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and conserved across vertebrates [39-42]. Thus, we postulated Id1-induced hPSC-CM, 
originated from the first heart field, have the potential to differentiate into VCM in 
spontaneous differentiation condition, and ACM by activating RA signaling pathway. 
To test the hypothesis, first, we ask whether promoting RA signals to Id1-induced 
CMP would affect cardiogenic potential [Figure 3.1A]. We provided different 
concentrations of RA cues on day 5 Id1-induced CMP and performed ACTC1 
immunofluorescent staining on day 15 [Figure 3.1B]. The result shows that the RA 
Figure 3.1 CM subtype (ventricular and atrial-like CM) differentiation. (A) Schematic diagram of CM 
subtype differentiation protocol. (B) RA dose-dependent cardiac differentiation efficiency indicates optimal 
dose range of RA during ACM differentiation. (C–D) Cardiac differentiation efficiency is not effected by the 
addition of RA. (E–F) Atrial-specific transcription factor NR2F2 was highly expressed in the RA-induced 
ACM. (G) qPCR showed subtype-specific marker genes were highly expressed in CM subtypes. 
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concentration between 30 nM to 300 nM, the cardiac differentiation efficiency was not 
substantially affected. Also, the optimal RA concentration that has minimal impact on 
differentiation is cell-number dependent, for example, 384-well plate format with 2 x 104 
cells, media volume 100 µl per well and RA concentration 160 nM. Thus, RA molecules-
per-cell could be calculated as 8 x 1016 mole per cell, and the concentration varies according 
to different differentiation format. Collectively, we established optimal RA concentrations 
for various plating formats without reducing the efficiency of cardiomyocyte 
differentiation compared to the spontaneous basal media differentiation. 
Next, to validate the molecular differences between spontaneous differentiated 
CMs and RA-treated CMs, we selected NR2F2 as the marker for ACM. Based on previous 
reports, orphan nuclear receptor transcription factor NR2F2 (COUP-TFII) regulates atrial 
identity in mouse and leads to severe atrial abnormalities in loss-of-function mouse mutant 
[43, 44]. NR2F2 expression level was substantially up-regulated in the RA-treated 
condition comparing with the spontaneous differentiation on day 15 CMs [Figure 3.1C–F]. 
Additionally, we performed qPCR on ventricular (IRX4 and MYL2) and atrial marker 
genes (TBX5, KCNA5, and NR2F2). The ventricular markers were significantly expressed 
in CMs with spontaneous differentiation, and in contrast, atrial markers were markedly up-
regulated in RA-treated condition [Figure 3.1G]. In summary, based on the 
immunofluorescent and qPCR results, Id1-induced CMPs spontaneously differentiate into 
VCM, and with exogenous addition of RA during cardiomyocyte differentiation, CMPs are 
effectively directed toward ACM. 
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3.2.2 Unbiased Transcriptome-wide Analysis Identify Distinct Cell Populations 
Representing Ventricular-like and Atrial-like Cardiomyocyte 
To further elucidate the differentially active molecular programs between CM 
subtypes, we performed the whole transcriptome RNA sequencing (RNA-seq) on ACM 
and VCM at two different time points, day 13 and day 25 of differentiation [Figure 3.2A].  
Fibroblast growth factor (FGF) signaling pathway has been found to directly 
regulate transcription factors that mediate the formation of ventricles [45]. FGF family 
members FGF8 and 10 are highly up-regulated in the VCM. The receptor FGFR, as well 
as the downstream target of FGF signaling including ETS1, ETV5, HES1, and FOXC1, 
were differentially expressed in the VCM. Also, NOTCH signaling plays an essential role 
in balancing the proliferation and differentiation during heart development. More 
specifically, NOTCH signaling pathway regulates cell fate decision and is crucial for 
ventricular chamber development [46]. NOTCH2 and its downstream targets BMP10, 
NRG1 and HES1 were highly expressed in the VCM. HOPX, transcription factor that binds 
and regulates HDAC2, which has been known to strictly controlling left ventricle function, 
is also up-regulated. Additionally, SOX6 as an inhibitor of NPPA, a well-studied atrial 
marker, was also differentially and explicitly expressed in the VCM.  
In contrast, in the early time point (Day 13), targets of RA signaling, including 
RORA, HOXB3/4, and NFY-B were found increased in ACM. Master regulator of the 
atrial specification, NR2F2, also known as COUP-TF II, was differentially expressed in 
ACM [43]. Also, TBX5, TBX20, and GATA6, crucial atrial-specific transcription factors 
during development, were highly expressed in ACM. In the later time point (Day 25), 
NPPA and NPPB were also highly expressed in the ACM, which have been shown 
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regulating multiple aspects of atrial function [47]. Several transcription factors related to 
the expression of NPPA were all differentially expressed in ACM, including the up-stream 
targets, GATA6 and ATF2, and the down-stream targets JUNB, EGR1, EGR2, and EGR3. 
Transcription factor PITX2, known for the co-regulation of multiple atrial-specific genes 
with TBX5, was up-regulated in ACM. Atrial-specific metabolic enzyme TECRL was 
highly expressed in ACM. Lastly, HIF3A and SMAD9, related to atrium development and 
function, were overexpressed in ACM. In summary, we identified several transcription 
factors related to FGF and NOTCH signaling, ventricular morphology and functions were 
up-regulated in VCM. Conversely, transcription factors in the RA signaling pathway, 
NPPA regulatory network, as well as atrial-specific metabolic enzyme TECRL, were 
differentially expressed in ACM. 
CM subtypes also display functional differences in action potential morphology and 
contractility. These differences could also reflect on differentially expressed ion channels 
and contractile proteins between the subtypes. KCNA5, responsible for atrial-specific 
ultrarapid delayed rectifier potassium inward current IKur, and KCNJ3, member of G 
protein-coupled inwardly-rectifying potassium channel IKACh, were both up-regulated in 
ACM. Myl2, a structural protein that is responsible for ventricular sarcomere formation, 
was up-regulated in the VCM. However, we did not observe remarkably expression 
differences in Myl7, which is an atrial-specific isoform of myosin light chain. GJA5, a 
protein component of gap junctions that expressed exclusively in atrial myocytes and is 
crucial for electrical impulse conductions, was significantly expressed in the ACM. Next, 
we performed principal component analysis (PCA) upon populations and asked whether 
the analysis could distinguish distinct CM subtypes arise from our differentiation protocol 
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unbiasedly. Informative PCA components clustered cells into four groups [Figure 3.2B]. 
Clusters were clearly segregated by temporal differences (PC1) and CM subtypes (PC2). 
Moreover, gene ontology result also reveals several gene cluster differences between VCM 
and ACM. They could be categorized into three major groups: (1) Ion channels and action 
potential; (2) Cardiac conduction; and (3) Muscle development and contraction. With all 
the gene ontology terms (GO-terms) fold enrichment > 9, there are total 4 related to ion 
channels and action potential, “Membrane depolarization during SA node cell action 
Figure 3.2 Molecular validation of CM subtypes in two different timepoint (VCM at day 13, VCM at day 
25, ACM at day 13, ACM at day25). (A) RNA-sequencing result of all four conditions showed distinct gene 
expression culsters. (B) Four major clusters were observed in principle component analysis. (C) Five GO-
term related with cardiac functions with fold enrichment > 9 were listed, indicates differentially expressed 
genes in CM subtypes results in functional difference between CM subtypes. 
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potential” (GO:0086046), “Cardiac muscle cell action potential” (GO:0086001), 
“Potassium ion import across plasma membrane” (GO:1990573), and “Calcium ion import” 
(GO:0070509). Next, there are 3 GO-terms involved in cardiac conduction, “Cell-cell 
signaling involved in cardiac conduction” (GO:0086019), “Regulation of heart rate by 
cardiac conduction” (GO:0086091), and “Cell communication involved in cardiac 
conduction” (GO:0086065). Lastly, 4 GO-terms that could be categorized in muscle 
development and contraction, which include “Cell migration involved in heart 
development” (GO:0060973), Cardiac muscle cell action potential involved in contraction” 
(GO:0086002), and “Cardiac muscle cell contraction” (GO:0086003). These GO-terms 
coincide with the functional validation data of action potential, calcium transient, and 
contraction showed in the following section. 
 
3.2.3 Action Potential Assessment on Ventricular-like and Atrial-like 
Cardiomyocyte 
Heart, responsible for propelling blood throughout the body and lungs, has precise 
and sophisticated mechanisms to initiate and maintain the contraction in rhythm throughout 
our entire lifespan. The pumping action requires highly coordinated efforts from the 
generation of action potentials to the CICR process that further triggers the contraction and 
relaxation of the muscle fibers[Figure 3.3A] [48]. Miss-regulations of the process could 
quickly lead to varies heart diseases, such as arrhythmia and cardiac arrest [49-51]. 
Cardiomyocytes in the atria and ventricles are functionally distinct in their 
electrophysiological and contractile properties [24, 52, 53]. Thus, a thorough 
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characterization of the cardiac physiology of VCM and ACM is essential for further 
applications. 
The cardiac action potential can be categorized into five distinct phases; the 
membrane depolarization of rapid activation of inward Na+ current (phase 0), followed by 
transient repolarization (phase 1), and a plateau phase due to the counterbalance between 
inward Ca2+ current and outward K+ current (phase 2). Afterward, membrane potential 
quickly repolarized (phase 3) then restore back to the resting state (phase 4) and ready for 
another cycle [Figure 3.3B]. 
Whole-cell patch-clamp is a common technique used to measure the action 
potential and the activation/inactivation of the ion channels. Cardiomyocytes in the 
electrophysiological perfused chamber were patched by glass pipettes. The recording was 
Figure 3.3 CM functional assement through action potential, calcium transient, and contractility. (A) 
Simplified CM function cartoon. Action potential: membrane potential is initiated by the 
activation/inactivation of various ion channels (Na+, Ca2+, and K+). Calcium transient: elavated intracellular 
Ca2+ concentration then induces CICR cycle. Contractility: intracelluar Ca2+ bind and facilitate the 
contraction of myofilment. (B) Action potential traces is the synergistic result of a sequce of 
activation/inactivation of ion channels. The composition of ion channels are differentially expressed on the 
membrane of CM subtypes which leads to distinct action potential morphology. Various action potential 
durations (APDs), the depolariztion and replariztion time (TDepol and TRepol) are measured as parameters to 
discribe the shape of the action potential traces. 
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then performed in Tyrode’s solution, and the current response was acquired using an 
amplifier. The result displayed that VCM had a faster and steeper upstroke during the phase 
1 depolarization. The average APD75) ranges between 200 to 300 milliseconds (ms), and 
the resting membrane potential (VRest) was around -60 to -80 millivolts (mV) [Figure 3.4A]. 
The ACM had shorter APD75 values, around 60 to 120 ms, and similar VRest to VCM 
[Figure 3.4B]. The action potential of VCM exhibits prolonged plateau phase 2, which is a 
typical hallmark of ventricular cardiomyocyte action potential traces, and in contrasts, the 
action potential traces of ACM showed a triangular-like morphology, which is the most 
pronounced difference between atrial and ventricular action potential waveforms. 
To gain insight into the cardiomyocyte sub-type electrophysiology in a more 
unbiased and efficient way, we performed the action potential analysis on the automated 
high-throughput fluorescent-based kinetic image acquisition platform with McKeithan et 
Figure 3.4 Action potential analysis indicates functional differences between VCM and ACM. (A–B) Patch-
clamp electrophysiology demostrate action potential morphylogy difference between CM subtypes, where 
VCM has longer and plateu-like shape in phase 2, and ACM has a more triangular-like shape morphology. 
(C–D) Flourascent-based voltage-sensing probe analysis showed similar action potential morphoogy with 
patch-clamp elctrophyiology. (E–H) Quantification result of APD50, APD75, depolarization time (recorded 
under 225 Hz), and traiangulation. 
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al [54]. Briefly, this co-developed platform acquires time-series images with high-
speed/high-resolution automated microscopy. Incubating cardiomyocytes with a fast 
response membrane potential sensitive probe (FlowVolt) which intercalates into the plasma 
membrane and senses changes in transmembrane potential by photo-induced electron 
transfer (PeT) mechanism enabled us to record membrane potential fluctuation through 
florescent signals [55]. Remarkably, action potential waveforms had matching features 
compared with traces retrieved from the whole-cell patch-clamp and published in vivo data, 
with prolonged phase 2 in VCM and triangular-shape in ACM [Figure 3.4C–F] [56]. We 
next examined the depolarize time (TDepol) differences between the two sub-types. Utilizing 
the high frame-rate microscopy that is capable of recording up to 225 Hz, we could 
distinguish the temporal difference during the rapid depolarization of phase 1. Consistent 
with the result in whole-cell patch-clamp experiment and published data, VCM had faster 
Tdepol for less than 20 ms, and the time ACM took to reach full depolarize state is doubled 
[Figure 3.4G] [57]. Triangulation parameter (APD30 - APD90) provide an additional aspect 
to quantify the plateau and repolarization phases of the action potential. As expected, due 
to the prolonging of phase 2 in VCM, it had greater triangulation, whereas, in ACM, the 
faster repolarization leads to lower triangulation [Figure 3.4H]. Collectively, consistent 
results in whole-cell patch-clamp and fluorescent-based kinetic image acquisition platform 
elucidate the action potential morphology differences between VCM and ACM, which in 
turn are the manifestations of the underlying different ionic currents in distinct 
cardiomyocyte subtypes. 
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3.2.4 Calcium Transient and Contractility Assessment on Ventricular-like and 
Atrial-like Cardiomyocyte 
Calcium handling is the critical intermediary of the excitation-contraction coupling, 
the process of electrical stimulus triggering the contraction and relaxation of the muscle 
fiber. During the course of an action potential, the membrane was depolarized thereby 
inducing the activation of L-type calcium channels that activate the inward L-type Ca2+ 
current (ICaL), which contributes to the plateau part of the phase 2 action potential. 
Cytoplasmic calcium ion concentration then accumulates and subsequently triggers the 
opening of the Ryanodine receptor type 2 (Ryr2) and induced massive Ca2+ release from 
the sarcoplasmic reticulum (SR) [48, 58]. The influx signal of inward Ca2+ is known as the 
“calcium sparks,” and the process of Ryr2 activation induced by prominent levels of 
cytoplasmic Ca2+ concentration is named CICR. Significantly raised cytoplasmic Ca2+ 
level facilitates the binding of Ca2+ to the cardiac troponin, exposing myosin binding sites 
and switching on the contractile machinery. During the muscle relaxation phase, Ca2+ is 
mainly recycled through Sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) back to the SR, 
partially got extruded out of the cell by Sarcolemmal Na+/Ca2+ exchanger (NCX) [Figure 
3.3A]. 
To better characterize and assess the calcium handling differences between VCM 
and ACM, we incubated cardiomyocytes with the fluorescent Ca2+ indicator (Flow4-NW) 
which emits strong fluorescence upon binding with cytoplasmic Ca2+. We imaged cells 
under the kinetic image acquisition platform and calculated physiological parameters from 
the fluorescent-change-over-time calcium transient traces. As expected, the calcium 
transient duration from the induction to relaxation lasted much longer compared to the 
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action potential duration [Figure 3.5A–B]. Quantitatively, calcium transient duration at 
50% and 75% of relaxation (CTD50 and CTD75) of VCM is greater than ACM [Figure 3.5C-
D]. Altogether, calcium transient morphology and CTDs showed distinct features of VCM 
and ACM, which also coincide with previously reported data [59]. 
In addition to calcium handling, contractile force production is the central 
participant of the excitation-contraction coupling machinery. To characterize the 
contractility differences between cardiomyocyte subtypes, we labeled the cellular 
membrane with wheat germ agglutinin (WGA), and record the contracting cardiomyocyte 
with the high-speed microscopy. By measuring the membrane movement with pixel-to-
pixel comparison algorithm, we are able to retrieve the contraction speed and rate of the 
cell. The rate of active tension generation (TRise) and relaxation (TDecay) were faster in ACM 
than VCM, which are consistent with previous findings [Figure 3.5E–H] [53]. In summary, 
Figure 3.5 Distinct functional differences between CM subtypes on calcium transient and contractility. (A-
B) Calcium transient analysis through calcium-sensing probe showed VCM has longer calcium transient 
duration compares to ACM. (C–D) Quantitative measeurment of CTD50 and CTD75. (E–F) Pixel tracking 
algorithm reveals difference in contractility (contracting speed) between VCM and ACM. (G–H) 
Quntification result of contractility on curve rising and decay time (TRise and TDecay). 
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we have functionally validated the subtypes on calcium handling and contractility. We 
concluded that VCM has elongated calcium transient morphology and slower contraction 
speed both in TRise and TDecay comparing to ACM. 
 
3.3 Discussion 
3.3.1 Retinoic Acid Signaling is Crucial for Atrial-specification 
During vertebrate development, body plan is determined by signaling gradients in 
complex spatiotemporal manner. RA has a central role during early embryogenesis and 
later stages of heart morphogenesis [60-62]. RA is synthesized through the oxidization of 
retinol (dietary vitamin A) to Retinaldehyde by Retinol dehydrogenase 10 (RDH10), then 
oxidizes to RA by Retinaldehyde dehydrogenase (RALDH2), and further inactivated into 
polar metabolites by cytochromes. As a lipophilic signaling molecule, RA binds to nuclear 
RA receptors (RARs) and forms RAR-retinoid X receptor (RXR) heterodimer complex 
that binds to DNA located by RA response elements (RAREs) and regulates the 
transcription of target genes. Forming complexes with co-activators and co-repressors 
allows RA to mediate the activation or repression of target genes [61, 63]. During embryo 
development, RA gradient is carefully governed by the generation and degradation 
machinery. The combination of opposite gradients such as fibroblast growth factor-8 
(FGF8) and enzymatic inactivation of RA, enables the patterning and organogenesis of 
heart, liver, eye, forebrain, limb, and body axis [64-67]. 
The mammalian heart is formed by the migration, pattering, diversification, and 
acquisition of functions of cardiac progenitor cells. RA signaling has long been known to 
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play a critical part in heart morphogenesis, both excess retinoids and RAR or RXR 
knockout mouse models caused myocardial defects [68]. More specifically, vitamin A-
deficient quail embryos had close caudal and failed to form sinoatrial tissue. Mouse 
embryos treated with RA synthesis inhibitor or RALDH2 knockout mutations also showed 
sinoatrial morphological defects [39, 69, 70]. Furthermore, the overexpression or down-
regulation of TBX5, one of the downstream targets of RA signaling pathway, produced 
myocardial defects, indicating the essential role of RA regulating heart patterning and 
cardiomyocyte subtype-specification [71]. 
Consistent with our result, recent studies reported RA as an atrial-selective cue in 
the in vitro hPSC system [42, 72]. During differentiation, the addition of RA in early 
cardiac progenitor stage (Day 4-8), direct the differentiation towards ACM, conversely, 
spontaneous differentiation or applying RA inhibitor, BMS493, instruct the progenitor to 
become VCM. In summary, we successfully demonstrated cardiomyocyte subtype-specific 
differentiation from Id1-induced CMPs using RA as an atrial-selective cue. 
 
3.3.2 Id1-induced Cardiomyocytes have Distinct Gene Expression Landscape 
between Subtypes 
The opposing gradients of RA and FGF8 have been shown widely applied through 
the embryo body axis establishment and patterning of the heart [73, 74]. During heart 
chamber specification, the identity of cardiomyocyte progenitors remains relatively plastic.  
The role of FGF signaling in early-differentiation is to initiate ventricle development, and 
in later differentiation, to stabilize ventricular identify [45]. NOTCH, another crucial 
signaling pathway that involved in the specification of the ventricular CM subtype, is 
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shown active in the ventricular RNA-seq data [75]. NOTCH signaling is required in 
chamber patterning, ventricular myocardial differentiation. The activation of downstream 
NOTCH target also requires the NOTCH-dependent activity of BMP10 and NRG1 to 
promote the differentiation of ventricular myocardium, which could be seen up-regulated 
in the RNA-seq VCM data [46]. Lastly, the mutations in several NOTCH signaling 
elements underlie congenital heart diseases in the mouse model, indicating the importance 
of the signaling pathway during chamber specification [76, 77]. Collectively, the activation 
of FGF and NOTCH signaling suggest the ventricular-like identity in Id1-induced VCM. 
 
FGF signaling in the atrium is mediated and repressed via the upstream RA 
response complex RAREs. The RA-FGF antagonism, activation of RA and repression of 
FGF signaling pathway, further enhance TBX5 and TBX20 expression during atrial 
specification in vivo [71]. Haploinsufficiency mouse model of Tbx5 showed structural 
defects in the atrium and abnormally prolonged P-waves during atrial depolarization [78]. 
Additionally, NPPA, an atrial-selective marker that has been extensively used for the 
studying of the subtype-specific differentiation and transcriptional regulatory pathways in 
cardiac gene regulation, is involved in multiple atrial-specific transcriptional pathways. 
NPPA, as a downstream responsive element of the NKX family, GATA family, and TBOX 
family, revealed its essential and selective role of the molecular mechanisms regulating 
regionalized cardiac expression and atrial subtype-specification [47, 79]. Atrial-abundant 
ultra-rapid delayed rectifier K+ current (IKur) and acetylcholine-sensitive K
+ current (IKAch), 
encoded by KCNA5 and KCNJ3, are the primary determinates of electrophysiological 
difference between CM subtypes. Ventricular CMs have a prolonged plateau-like phase 2 
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morphology, and atrial CM has shorter and triangular-like traces due to the selectively 
expressed K+ channels IKur and IKAch in humans [57]. The selective expression of KCNA5 
and KCNJ3 in ACM from the RNA-seq result reflects the electrophysiological differences 
between Id1-induced VCM and ACM. In summary, various genes involved in atrial-
specification during the heart development and chamber patterning, as well as in atrial 
physiology are up-regulated in the Id1-induced ACM, confirm the atrial-like molecular 
identity of the resulting ACMs.  
 
3.3.3 Subtype-Specific Cardiomyocyte Differentiation Provides a Physiologically 
Relevant System for Cardiac Disease Modeling and Drug Discovery 
Cardiomyocytes in the atria and ventricles are not only molecularly, but also 
functionally distinct. Functionally, they differ significantly in electrophysiology, calcium 
handling, and contractile properties. To generate stronger contraction force due to the 
increased calcium influx via L-type calcium channels in phase 2, VCM has faster 
depolarization speed and stronger inward sodium current (INa), as well as lesser transient 
outward current (Ito). The most noticeable difference in morphology of action potential 
between the subtypes is the duration of the depolarized plateau (phase 2). The membrane 
potential was carefully balanced by inward ICaL through L-type calcium channels and 
outward potassium flux (IK) through various potassium channels. To produce higher 
contraction force, stronger calcium influx and more extended calcium channel activation 
are required in VCM. Conversely, outward potassium currents, including slow (IKs), rapid 
(IKr), and inward delayed rectifier (IK1) are stronger in ACM, along with atrial-abundant 
IKur, resulting in faster repolarization and shorter action potential duration [Figure 3.3B] 
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[24, 80]. Coherent with the result, Id1-induced VCM has more extended depolarized 
plateau and ACM has shorter and more triangular action potential waveform. 
 
Due to strong activation of ICaL and higher Ca
2+ content in SR in VCM, the CICR 
cycle lasts longer, in contrast to ACM [81]. Moreover, SERCA2a, which involved in 
recycling cytoplasmic Ca2+ back into SR, is abundantly expressed in the atrial 
cardiomyocyte, which lowers systolic Ca2+ transient and therefore leads to rapid relaxation 
of the atrial myocytes [82]. Myofilaments require the binding of Ca2+ to reveal the myosin 
binding sites and initiate the contraction. Thus, elevated Ca2+ level in VCM produced 
stronger and long-lasting contraction forces. On the contrary, mechanistically, served as 
blood reservoirs for the passive and active filling of the ventricle, atria have both faster 
tension generation and relaxation than ventricle [53]. These findings correlate with our 
subtype-specific functional data of calcium transient and contractility rate in VCM and 
ACM. The results confirm the physiological relevance of Id1-induced cardiomyocyte 
subtypes and the potential of modeling cardiac disease in a subtype-specific manner. 
 
3.4 Conclusion 
To target the atrial-specific target space of AF, RA was administered to generate 
ACM from CMP. The resulting ACMs were than validated molecularly through qPCR, IF, 
and RNA-seq. The data suggest atrial-specific genes were highly expressed in the ACM, 
whereas the ventricular-specific genes were up-regulated in the VCM. Furthermore, the 
differentiated CM subtypes were also functionally validated in action potential, calcium 
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transient, and contractility. All 3 functional aspects resemble the physiology features 
observed in adult human cardiomyocyte subtypes. In summary, the resulting ACM present 
atrial-specific features both molecularly and functionally. 
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Chapter 4  
 
Single-cell High-throughput Functional 
Screening Platform for Arrhythmia 
Modeling 
 
 
 
 
 
4.1 Background 
Being able to generate unlimited amounts of Id1-induced hPSC-derived ACM and 
VCM made connecting gene variants to disease phenotypes, modeling cardiac disease in-
a-dish, and conducting large-scale screens for discovering novel therapeutic targets 
possible. However, a major hurdle of implementing the cells for further application is the 
lack of throughput due to conventional methods, that are costly, time-consuming, and 
technically challenging. To better advance the efficiency and increase the robustness for 
monitoring action potential and conduct in vitro phenotypical screenings, we established a 
subtype-specific cardiomyocytes high-throughput platform with single-cell resolution 
functional readouts. This platform integrates automated liquid handler, high-speed 
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microscopy with the optical recording of fluorescent dyes, which enable the monitoring of 
membrane potential, calcium transient, or contractility [Figure 4.1A–C]. Furthermore, the 
analysis algorithm enables the segregation of single-cell level cellular autonomous activity 
from the whole-well, providing an in-depth physiological matrix for individual 
cardiomyocytes [Figure 4.1D–F]. The technique can be readily adapted to common high 
content automated imager to study cardiomyocyte physiology in vitro for arrhythmia 
modeling and phenotypical screening applications. 
 
Figure 4.1 Schematic diagram of high-throughput single-cell functional screening platform workflow. (A) 
ACMs were replated into 384-well plate and recoverd for 72 hours. (B–C) Voltage-sensing probe were added 
and incubated for 45 minutes, and cells were than imaged by high-speed microscopy with 20x, 100 Hz, 5 
second recording. (D) Movies were analyzed by software and generate reagion of interests (ROI) via nucleus 
masks. (E) Flourescent intensity of each ROI was measured and action potential traces for each cell were 
generated. (F) Single-cell physiology metrics were then retrieve by trace analysis algorithm. 
  44 
4.2 Results 
4.2.1 High-throughput Single-cell Functional Assessment Platform 
Current cardiomyocyte-related physiology studies were commonly performed on 
the whole-cell patch-clamp technique that provides information on ion channel activities 
and the transmembrane potential status.  However, the primary constraint of patch-clamp 
electrophysiology lies in the limited throughput (around 12 cells per day). The technique 
is more suited in the later phases of candidate validation, whereas the primary candidate 
identification should be conducted in systems with unbiased screening strategies and higher 
throughput. 
To establish the high-throughput single-cell functional assessment platform, liquid 
handler (Microlab Star, Hamilton) with environmental control is integrated for CM 
culturing and dye incubation in 384-well micro-pipette plate format [Figure 4.1A]. 
Fluorescent-based automated microscopy acquires high resolution (up to 40x) and frame 
rate (up to 225 Hz) videos [Figure 4.1B]. To evaluate CM physiology and model 
arrhythmia in-a-dish, we focused on cell-autonomous activities and local cell cluster 
behavior. Plating density was carefully modified to deliberately avoided the mono-layer 
culturing condition. Sparsely plated 4,000 cardiomyocytes per well of 384-well plate, 
provide the state that the electrical syncytium appears locally between proximate clusters, 
but not in a whole-well level, as it was in the mono-layer culturing condition [Figure 4.1C]. 
Next, to achieve single-cell action potential resolution, analysis software generates the 
region of interests (ROIs) via DAPI nucleus staining before acquiring movies. The image 
analysis software processed the fluorescent-change-overtime in individual ROIs that 
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represents each cell within the field of view to obtain specific action potential traces for 
each cell recorded [Figure 4.1D]. Action potential traces were then analyzed by the 
algorithm described in the following section to retrieve single-cell physiology data. In 
summary, consolidating CM subtypes with automated microscopy and analysis algorithms, 
the single-cell resolution functional assessment platform is a novel technology for high-
throughput phenotypical screenings and arrhythmia modeling in-a-dish. 
 
4.2.2 Algorithm of Retrieving Physiological Relevant Metrics for Arrhythmia 
Modeling 
To retrieve physiological metrics from extensive data of single-cell action potential 
kinetic imaging, stream-lined data analysis, and batch processing are required. The data 
handling could be divided into two main parts: the retrieval and conversion of fluorescence-
intensity-changes-overtime to action potential traces; and the interpretation and 
categorization of physiological metrics from the traces [Figure 4.1E–F]. 
First, the kinetic images were processed through built-in image processing software, 
MetaAnalysis. By overlaying the acquired image stacks with nucleus staining, the software 
transformed the local fluorescence-intensity-changes-overtime into action potential traces 
for individual cells. Each cell was also given a specific tag containing information 
including plate/well/cell IDs and relative position in the well. The data were then 
transferred to the cloud-based trace analyzer. The algorithm of trace analyzer was written 
in R and uses the Prama package for initial peak and pit detection.  The algorithm uses a 
combination of statistical heuristics, an input threshold value, and control well activity 
statistics to remove random noise, categorize well activity, and retrieve physiology metrics 
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and statistics in both bulk (well-based) and single-cell (cell-based) format.  Well activity is 
categorized into one of four types, Inactive; the cells did not produce enough of a response 
to be considered for further analysis, Type 1; regular activity, Type 2; extended action 
potential duration, or Type 3; abnormally escalated peak counts.  The algorithm produces 
a PDF of all cell activity with highlighted peaks as well as useful summary statistics such 
as action potential duration at 90%, 75%, 50%, 25%, 10% of repolarization (APD90, APD75, 
APD50, APD25, APD10), peak-to-peak interval, number of ectopic peaks, peak rise/decay 
time, frequency, and more [Figure 4.2].  In conclusion, automated batch trace analysis 
software and algorithm enabled efficient data processing of the single-cell functional 
assessment of cardiomyocytes.   
 
4.2.3 Single-cell Action Potential Assessment 
To validate the single-cell functional assessment platform, we asked how does the 
action potential readouts between CM subtypes correlate to the results from patch-clamp 
physiology or mono-layer culture whole-well analysis. We firsts sparsely plated VCM and 
ACM respectively. After 2 days, cells were incubated with voltage sensing probe, imaged, 
and action potential traces were analyzed with single-cell analysis algorithm. The median 
Figure 4.2 Physiology metrics of single-cell action potential trace analysis. 
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APD75 of the cells were calculated and binned into groups of 10 ms. Data was then 
presented through population distribution diagram with APD75 as x-axis and percentage 
frequency from the entire sampled population as the y-axis. The most noticeable feature of 
action potential morphology of a VCM is the elongated plateau of phase 2 that leads to 
longer APD. On the contrary, ACM presents shorter phase 2, with a more triangular-like 
shape of the action potential that has much shorter APD. The result showed that APD75 of 
ACM population clustered between 100 – 130 ms, with a median value of 115.6 ms, where 
the APD75 of VCM population clustered between 150 – 200 ms, with a median value of 
181.5 ms [Figure 4.3A–C]. In this data, 147 ACMs and 73 VCMs were recorded and 
analyzed. Collectively, the action potential durations and morphologies match the data 
recorded via patch-clamp physiology and mono-layer culture whole-well analysis, 
suggested that the single-cell action potential assessment platform provide relatively 
accurate physiology results and an additional layer of in-depth cell-autonomous activity 
information, without sacrificing the throughput. To emphasize the advantages of the 
Figure 4.3 Single-cell action potential analysis on ACM and VCM. (A) ACM population distribution 
diagram of APD75 indicated general population of ACMs had APD75 between 100 – 130 ms, with  triangular-
shape like representitive traces. (B) VCM population distribution diagram showed the general APD75 ranged 
between 150 – 200 ms, with plateau-like shape during phase 2 of action potential. (C) Avearage APD75 of 
ACM and VCM. Compares to average result, poulation distribution diagram of single-cell APD75 analysis 
provides higher resolution of data. 
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platform, we co-cultured VCM and ACM in two distinct formats, mono-layer electrically 
coupled format, and sparsely plated single-cell-like format [Figure 4.4A–B]. The action 
potential was them analyzed through whole-well fluorescent readout and single-cell 
segregation readout respectively [Figure 4.4C–D]. As predicted, the whole-well analysis 
of action potential morphology of mix-cultured CM has action potential durations in 
between pure VCM population and ACM population. The result suggested that the 
subtype-specific action potential phenotype might be masked by an opposing effect on 
another in an electrical syncytium of multiple cell types. In the single-cell analysis, the 
system was able to detect two separate populations representing ACM and VCM in the 
mix-culture format. In summary, the result indicates the high sensitivity of the platform 
and highlight the ability to retrieve more accurate data from mix-population culture. 
 
Figure 4.4 CM subtype co-culture experiments demonstrated the higher sensitivity of single-cell analysis. 
(A–B) ACM and VCM were co-cultured under desired density for single-cell and whole-well analysis. (C) 
Single-cell analysis was able to identify two distinctive populations with different action potential duration 
representing the subtpyes. (D) The whole-well action potential analysis of the mix population was situated 
in between the pure population of ACM and VCM with an intermediate action potential duration. 
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4.2.4 Atrial-like and Ventricular-like Cardiomyocyte Presented Differential 
Responses to Small Compounds 
The potassium channel Kv1.5 is more abundant in human atrial than in ventricular 
cardiomyocytes, which contributes to the functional difference between the two chambers 
[83, 84]. Kv1.5 is encoded by the gene KCNA5, and responsible for the IKur, which is the 
basis for balancing the membrane potential at phase 2 and initiating the repolarization at 
phase 3 in the human atria.  
To evaluate the subtype-specificity responses and exam the sensitivity of the 
platform, we acutely treated VCM and ACM with compounds that exclusively effect 
specific CM subtype. 4-aminopyridine (4-AP), a small organic compound, is a K+ channel 
blocker that has high selectivity on the KCNA family. To assess the effect of 4-AP on CM 
subtypes, the cells were acutely treated with the compound before image acquisition. 
Population distribution diagram of APD75 and representative action potential traces were 
then generated. In accordance with expectation, APD75 of ACMs were generally prolonged 
due to the blockade of Kv1.5 by 4-AP, and no increase of APD75 observed on VCM [Figure 
4.5A–B]. The data implicate the inhibition of Kv1.5, via 4-AP, induced prolongation of the 
action potential duration only in the ACM-specific manner. 
Cytoplasmic Ca2+ concentration is critical throughout the CICR process. VCM, 
which generate stronger contraction force, relies on abundantly expressed L-type voltage-
gated calcium channels [81]. The strong inward calcium current ICaL produced the 
elongated plateau phase in VCM action potential traces, whereas in ACM, L-type voltage-
gated calcium channels are mildly expressed. To assess subtype-specific response on 
differentially expressed L-type voltage-gated calcium channels, we acutely treated both 
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CM subtypes with nifedipine, an inhibitor of the influx of Ca2+ current by stabilizing the 
L-type voltage-gated calcium channels in their inactive conformation. As expected, VCM 
action potential is markedly shortened with the treatment of nifedipine, and the shortening 
effect of action potential duration is not significant in ACM [Figure 4.5C–D]. Based on 
these results, the single-cell action potential assessment platform provides a high-
throughput physiological readout useful for action potential-related disease modeling and 
pharmacological target discoveries in a subtype-specific CM manner. 
 
Figure 4.5 ACM and VCM responded differentially with the treatment of compounds, 4-AP and nifedipine 
that have subtype-specific effects. (A) Population distribution of APD75 of ACM treated with/without 4-AP. 
APD75 of ACM were prolonged after 4-AP treatment. (B) Population distribution of APD75 of VCM treated 
with/without 4-AP. No significant change of APD75 after 4-AP treatment. (C) Population distribution of 
APD75 of ACM treated with/without Nifedipine. APD75 of ACM were slightly shortened after nifedipine 
treatment. (D) Population distribution of APD75 of VCM treated with/without nifedipine. APD75 were 
dramatically shortened after nifedipine treatment. 
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4.3 Discussion 
4.3.1 Advantages of the Platform 
The modeling of arrhythmia in-a-dish and the identification of atrial-specific 
antiarrhythmic are the significant hurdles for the advancement of current pharmacological 
treatment of AF [85]. This fully automated system integrated with a liquid handler, high-
throughput microscopy, and trace analysis software, formulates a simple yet powerful 
workflow for phenotypical screens and cardiac disease modeling. Compatible screening 
libraries including small compounds, microRNAs, siRNAs, lentiviruses, and CRISPRa 
(CRISPR activation) enables complex cross-library screens, counter screens, or sensitize 
screens. Several compelling advantages of the platform that would substantially advance 
the field including subtype-specific CM as a more physiologically relevant biological 
system; greater throughput comparing to currently available systems; stronger statistical 
power generated via single-cell analysis; less cellular materials required; analysis based on 
population provides insight in modeling local arrhythmia-like behaviors. 
To further investigate the atrial-specificity of AF and the disease-causing 
mechanism, as well as developing antiarrhythmic treatments that unambiguously targets 
only the atria, the modeling and screening system require the specific atrial target space. 
Thus, applying ACM in the assay provides a more physiological relevant biological system. 
From kinetic imaging to data retrieval, the streamlined workflow can process a fully 
loaded 384-well plate within less than 6 hours, with more than 27 million data points 
analyzed. The technique significantly increased the throughput as well as the statistic 
power of data analysis. Compare to the typical whole-well analysis, which generates one 
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“n” per well, and patch-clamp electrophysiology, with much lower throughput and time-
consuming, single-cell analysis generates more than 70 “n” per field of view, and could 
easily expand the “n” via increasing additional imaging sites during the recording. 
Furthermore, the massive sample size unbiasedly represents the spectrum of the observed 
phenotypes across the entire population. Rather than only taking the mean value of the 
entire well, which frequently skewed the conclusion or overlooked substantial phenotype 
due to the heterogeneity within the culture. 
Sparsely cellular culture condition substantially reduces the usage of 
cardiomyocytes per experiment up to 5 times compared to the mono-layer culture condition. 
Reducing the number of cells required per experiment also markedly reduce the time and 
expenses for cell production, which on the other hand increase the throughput of screening.  
Lastly, single-cell analysis produces an additional layer of information specifically 
on cellular autonomous activities, which are crucial in modeling arrhythmia. The initiation 
of arrhythmia often appeared from local clusters such as the re-entry circuit which then 
propagates the ectopic electric stimulants to the neighboring cells and leads to arrhythmia 
[27]. On the contrary, the mono-layer culture condition is more appropriate for the studying 
of conduction functions due to the electrical syncytium of the cells. In summary, the high-
throughput single-cell functional assessment platform provides subtype-specific target 
space, display stronger statistical power without sacrificing the throughput, reduce 
cardiomyocyte usage, and generate a higher resolution of data particularly applicable to 
arrhythmia modeling. 
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4.3.2 Limitations of the Platform 
Limitations and critical areas for further improvement include the usage of fetus-
like cardiomyocytes which may not fully recapitulate the phenotype of a human adult 
cardiomyocyte. According to the RNA-seq result and recently published report, hPSC-
derived cardiomyocytes carry gene expression signatures similar to prenatal 
cardiomyocytes [86]. Further advanced CM maturation process may be required, and cross-
referencing the result with the in vivo model is also necessary. Although the optical 
recording is an efficient approach that visualized the alternation of membrane potential and 
calcium handling, it is an indirect readout that cannot provide information of the activation 
or inactivation of the ion channels. Thus, requires whole-cell patch-clamp method as a 
mean of validation. 
Also, due to the limitation of current microscopy system, we are unable to perform 
electrical stimulation on cardiomyocytes mimicking the aberrant electrical signal that 
triggers the fibrillation of the atria or increasing beat rate through pacing which sensitized 
the excitation-contraction coupling mechanism. However, other than the ectopic electrical 
signal, there are alternative triggers that may cause AF, including hormonal stimulations, 
ion channel agonists/antagonists, disrupting cellular calcium handling mechanisms, and 
abnormal electrical conduction. Finally, sparsely plated cardiomyocytes have poorly 
organized the sarcomeric structure and generate contraction tension from different angles, 
whereas the in vivo cardiomyocytes are tightly aligned with uniform contraction direction. 
A possible solution is plating cells on directional microgrooves plate, which restrict the 
orientation of sarcomeres[87, 88]. 
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4.3.3 Application of High-throughput Single-cell Resolution Functional 
Assessment Platform 
The tightly consolidated three factors made atrial arrhythmia in-a-dish modeling 
possible: (1) atrial-specific differentiation protocol that generates functional ACMs 
efficiently, (2) sparsely plated cell culture format that enables the occurrence of local 
arrhythmia-like behavior, and (3) single-cell action potential trace analysis provides in-
depth phenotypical readouts for each recorded cell. The system provides unique features 
for evaluating arrhythmogenic gene candidates and discovering potential antiarrhythmic 
targets that complement conventional arrhythmia research approaches, such as patch-
clamp electrophysiology, whole animals, or ex vivo heart preparations.  
In addition, induced pluripotent stem cell technology and CRISPR gene-editing tool 
allow unbiased functional screens to be performed on normal and patient-specific 
mutations, accelerating our ability to identify novel cardiac rhythm-associated genes and 
elucidating the mechanisms of action on the electrical remodeling of the cardiac action 
potential. Moreover, functional genomic screening of proteins or genes using siRNAs or 
miRNAs that could partially or entirely phenocopy the arrhythmia enables sensitized 
screen for novel therapeutic target identification and drug discovery. 
Most antiarrhythmics currently prescribed are nonspecific, regarding ion channels 
and heart chambers. The non-specificity of the targets may lead to serious off-target effect 
that could exacerbate the arrhythmia condition. Also, the non-specificity on both CM 
subtypes could create additional ventricular electrophysiology abnormalities that induce 
ventricular fibrillation (VF) or cardiac arrest while attempting to revert the atrial symptoms 
[89]. Thus, by conducting the subtype-specific screens provide physiologically relevant 
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target space for novel antiarrhythmic discovery. In summary, the platform provides an 
efficient way for both arrhythmia in-a-dish modeling as well as high-throughput 
phenotypical screenings for the identification of novel disease-associated gene candidates 
and antiarrhythmic drug discovery.  
 
4.4 Conclusion 
To achieve high-throughput screening efficiency, the platform was established in 
384-well plate format, and ACMs were replated with an automated liquid handler. Cells 
were incubated with the voltage-sensing probe and recorded via high-speed microscopy. 
Movies were then analyzed by single-cell image processing software, and physiology 
metrics were retrieved by trance analysis algorithm. Compare to conventional 
electrophysiology or whole-well action potential analysis, the system provides: (1) Fully 
automated and high-throughput efficiency. (2) Single-cell resolution of physiology 
assessment. (3) Large sampling ability. 
These features could greatly benefit the modeling of arrhythmia-like activity, due 
to sparse and electrically-uncoupled plating density with the aid of single-cell resolution to 
target specifically against irregular beating cells. Automated high-throughput and 
functional assessment aspect could advance the discovery of novel arrhythmia-causing 
gene candidates and antiarrhythmics. 
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Chapter 5  
 
Modeling Arrhythmia-like Activity with 
AF-associated Genes and Perturbagens 
 
 
 
 
 
5.1 Background 
AF contributes significantly to population morbidity and mortality and due to the 
poorly understood of its pathogenesis, presently available antiarrhythmic-based therapeutic 
approaches have major limitations including low efficacy and high off-target effect. Thus, 
there are unmet medical needs to deconvolute the pathogenesis pathways that lead to 
arrhythmia and further provide insights for novel antiarrhythmic development. 
Normal atrial cardiomyocytes display regular action potential changes over time, 
beginning from negative intracellular membrane potential (phase 0) and rapidly 
depolarized to the positive state (phase 1). During repolarization state, counteracts between 
Ca2+ influx and K+ efflux generates a short plateau shape of the action potential (phase 2), 
and then quickly repolarized back to the resting potential, at which it remains until the next 
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initiation of action potential cycle. Structural and electrical remodeling of the atria acts as 
substrates of AF which make atrial cells susceptible to aberrant electrical pulses from the 
pulmonary artery or atrial septum or other triggers such as parasympathetic activation, 
adrenergic stimulation, and aging [90-92]. Utilizing hPSC-derived ACM and high-
throughput phenotypical platform described in Chapter II and III, respectively, we are able 
to functionally evaluate genes previously associated with AF, as well as identify novel 
genes of cardiac rhythm in an atrial-specific manner. 
 
5.2 Result 
5.2.1 Quantitatively defined arrhythmia in-a-dish 
AF substrates can be categorized into two major groups, structural and electrical 
remodeling. Structural remodeling refers to the fibrosis of the cardiac tissue due to 
myocardial injuries such as myocardial infarction or surgical wounds [93]. The remodeling 
is composed of complex tissue morphology and lengthy duration that could be difficult to 
reproduce in cellular-based assays. Electrical remodeling, on the other hand, is the 
improper function of the ion channels that control cardiac cellular activity, which results in 
the prolongation and shortening of action potential duration. Under the effects of ectopic 
electric signals or other triggers, abnormal depolarizations may occur during or after the 
action potential plateau. Delayed afterdepolarizations (DADs) occur due to elevated 
cytosolic Ca2+ concentrations from the membrane Ca2+ channels or SR, NCX then 
propagates excess inward movement of 3 positively charged Na+ ions by extruding 2 Ca2+, 
and depolarize the resting membrane potential. With less negative resting membrane 
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potential, voltage-gated Na+ channel becomes more susceptible to aberrant electric signals 
and induce ectopic beats [Figure 5.1A]. Early afterdepolarizations (EADs) occur with 
abnormal depolarization during phase 2 or phase 3. When the duration of action potential 
and effective refractory period (ERF) are significantly prolonged due to the impair of 
repolarization mechanisms, either excess inward currents (for example ICaL or INa) and/or 
diminished outward currents (various potassium efflux currents), voltage-gated Ca2+ 
channel or voltage-gated Na+ channel is reactivated in phase 2 or phase 3 causing abortive 
action potentials, respectively [Figure 5.1B]. The shortening of action potential duration 
would lead to the occurrence of re-entry loop. When there are two alternate conducting 
pathways, a premature beat might engage one pathway with shorter ERF, while 
successfully traveling through the other pathway. The propagating impulse could travel 
around the loop indefinitely, causing rapid and sustained beating behavior that may spread 
to the rest of the heart [Figure 5.1C]. In summary, the prolongation of action potential 
duration could lead to abnormal afterdepolarizations DADs and EADs, and the shortening 
of action potential duration could trigger the re-entry circuit. 
Figure 5.1 Electrical remodeling (the prolongation or shortening of action potential duration) could increase 
the susceptibility of AF. (A) Normal ACM action potential trace morphology. (B) Prolonged action potential 
trace could trigger pre-mature ectopic beats such as early after depolarization (EAD) if occurred during phase 
2, or delayed after depolarization (DAD) in phase 4. (C) The shortening of action potential could induce rapid 
action potential cycle which than develop into a local re-entry loop. 
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Therefore, to quantitatively measure the arrhythmia-like behavior, we rely on two 
physiological parameters: action potential durations APD75 and the variation of peak-to-
peak intervals within the peak train [Figure 5.2A]. To efficiently identify the conditions 
with abnormal APD75 from massive data sets generated from the single-cell high-
throughput phenotypical platform, the medium APD75 from the peak train of each cell was 
calculated. Also, the ensemble phenotype from the formulation of the population regarding 
action potential duration was visualized via the APD75 population distribution diagram. 
The irregular peak-to-peak intervals could be quantified by the arrhythmia index (AI) 
derived from the following formula: 
𝐴𝐼 =
𝑆𝑡𝐷𝑒𝑣 (𝑝𝑒𝑎𝑘 − 𝑡𝑜 − 𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙)
𝑀𝑒𝑑𝑖𝑢𝑚 (𝑝𝑒𝑎𝑘 − 𝑡𝑜 − 𝑝𝑒𝑎𝑘 𝑖𝑛𝑡𝑒𝑟𝑣𝑎𝑙)
× 100 
AI describes the degree of irregular beating. Typical ACMs in control condition 
have AI less than 10, the higher the AI is, the more arrhythmia-like behavior the cell 
exhibits [Figure 5.2A–B]. According to different conditions, cells with varies AI values 
were plotted [Figure 5.2C]. Cells with AI under 20 presented relatively regular contracting 
activity, whereas cells with AI above 20 showed irregular peak-to-peak intervals with 
EADs/DADs in higher AI range [Figure 5.2D]. Thus, we consider cells with AI < 20 are 
in the “regular” category where no arrhythmia-like activities were observed; and cells with 
AI > 20 are in the “irregular” category where the arrhythmia-like activity occurred. 
Together, we could quantitatively and efficiently measure the degree of arrhythmia-like 
  60 
behavior in single-cell resolution based on the prolongation or shortening of APD75 along 
with the AI value. 
 
5.2.2 Functional evaluation of known atrial fibrillation-associated genes 
To further validate the system and examine data analysis pipeline, we functionally 
evaluated 20 genes previously associated with AF that were identified through rare variant 
studies and genome-wide association studies (GWAS) [94]. Rare variants are genetic 
Figure 5.2 Quntify the degree of arrhythmia-like activity with arrhythmia index (AI). (A) Action potential 
trace of regular beating ACM. Peak-to-peak interval remains fairly constant. (B) Example of action potential 
trace of ACM with arrythmia-like behaviour. (C) Example of poulation distribution diagram of AI indicates 
there were subpopulations with distinct AI value. (D) Representitive acion potential traces of several AI 
values. Cells with AI < 20 were consider as regular beating CMs. Cells with AI > 20 were consider as irreguar 
(arrhythmic-like) beating cells.   
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mutation identified within the cohorts of individuals with early onset (< 66 years) lone AF 
or familial AF which segregates as a Mendelian trait. Although several candidate genes 
have been validated in noncardiac-cellular models or animal models, it is still unclear 
whether variants in all of these genes are causative of AF in the patients. Furthermore, the 
studied cohort population and genes of interest were considerably small compares to the 
general AF population. On the other hand, GWAS studies on AF have identified 23 AF-
associated single-nucleotide polymorphisms (SNPs) [95, 96]. The candidate genes are 
genetic variants that reached genome-wide significance in the meta-analysis. However, out 
of these 23 gene candidates, only one is identified as an exonic SNP (gene CAND2), and 
the rest of 22 SNPs are located in the intron or intergenic regions. Although genetic 
knockout animal models of some of the candidate genes have shown cardiac defects or 
arrhythmias, there is no direct evidence that the identified SNPs directly lead to AF [97].  
We hypothesized that AF might be induced, not necessarily through genetic 
mutations, but through the dysregulation of the regulators of cardiac rhythm. Since rare 
variants and GWAS studies suggest an active link between candidate genes and AF, the 
overlap of the gene lists could act as positive controls for arrhythmia-like behavior induced 
by dysregulation of the candidate genes in our platform. The 20 overlapped gene candidates 
between rare variants and GWAS studies are listed below: 
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Table 5.1 List of previous known AF-associated genes identified through rare variant and GWAS. 
Rare variant GWAS locus Gene abbreviation Function category 
X X HCN4 
Ion channels 
X  KCNA5 
X X KCND3 
X X KCNJ5 
X X KCNN3 
X X GATA4 
Transcription 
factors 
X X GATA5 
X X GATA6 
X X HAND2 
X X NKX2-5 
X X NKX2-6 
X X PITX2 
X X TBX5 
X X ZFHX3 
X X GJA1 
Myocardial 
structural 
components 
X X GJA5 
X X SYNE2 
X X PLN 
X  NPPA 
Signaling 
X X SH3PXD2A 
 
To test the hypothesis, we performed siRNA-mediated knock-down on all 20 AF-
associated genes on day 25 ACMs. After 3 days, cells were incubated with the voltage-
sensitive probe, imaged, and analyzed with single-cell trace analyzer [Figure 5.3A]. The 
compiled results from different batches of cells and experiments showed that out of all the 
gene candidates, 4 showed consistently prolonged APD75, including GATA5, PITX2, 
KCNA5, and GATA6 [Figure 5.3B]. One showed shortening of the action potential 
duration, which is PLN. Among these gene candidates, GATA5 and 6 are the family 
members of the GATA-type zinc fingers, which involved in the regulation of cardiac 
development and adult heart [98]; PITX2 has an early role determining the asymmetry 
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during heart formation, and is one of the most significant AF-associated gene candidate 
reported from the GWAS study [99]; KCNA5 is an atrial-specific K+ channel, and both 
gain and loss-of-function mutations in patients have been directly linked to AF [100]; PLN 
regulate the CICR cycle through the inhibition of Ca2+ uptake ability of SERCA2a on SR.  
To elucidate the prolongation of action potential duration via siRNA-mediated 
knockdown against GATA5, KCNA5, PITX2, and PLN in the single-cell level, we 
analyzed and presented the data in APD75 population distribution plot and APD75-peak 
count plot. Based on the result of APD75 population distribution plots of siGATA5, 
siKCNA5, and siPITX2, the knockdown of these genes prolonged the cellular population 
globally, where the entire population right-shifted towards greater APD75 [Figure 5.4A–
C]. siGATA6 had minimal effect in prolonging action potential in ACM in the repeating 
experiments, thus was eliminated from the candidate list. In ACM transfected with siPLN, 
Figure 5.3 More than half of the previously known AF-associated genes induced electrical remodeling in the 
sytsem. (A) Schematic diagram showed the transfection of siRNA against 20 previously known AF-
associated genes to ACM. (B) Out of 20 previously known AF-associated genes, 8 siRNA leads to the 
prolongation of action potential duration and 4 shortens the action potential duration. 
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the entire population was left-shifted, indicating the knockdown of PLN shortens the action 
potential duration of the population [Figure 5.4D]. The number of peak counts and action 
potential duration are often correlated. Thus, to justify the phenotype of abnormal action 
potential duration is not the secondary result due to the increase or decrease of beat rate, 
we analyzed the alteration of action potential duration under fixed peak count. In all 3 
siRNA-mediated knockdown conditions, APD75 are greater in the primary population 
under fixed peak counts (highlighted in the squares) [Figure 5.5A–C]. Whereas in siPLN 
Figure 5.4 Transfecting siRNA against GATA5, PITX2, KCNA5, and PLN leads to electrical remodeling. 
(A–C) siGATA5, PITX2, KCNA5 prolongs the APD75 of ACM. (D) siPLN shortens the APD75 of ACM. 
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condition, the population shifts down-warded, suggests the main population has shorter 
action potential duration [Figure 5.5D]. 
In summary, siRNA-mediated knockdown of GATA5, KCNA5, PITX2 prolonged 
action potential duration under fixed peak counts, and siRNA against PLN shortened action 
potential duration. However, no arrhythmia-like activities were observed in all of the 
siRNA-mediated knockdown conditions [Figure 5.5E–H]. 
 
5.2.3 Induce arrhythmia in-a-dish with AF substrates and perturbagens 
The onset and sustain of AF require a susceptible substrate and perturbagens, 
usually provided by stimulations such as adrenergic or cholinergic, or an ectopic beat. Here 
we examined 3 known AF-associated perturbagens alone and in combination with siRNA-
mediated knockdowns as AF substrate to model and evaluate the occurrence of arrhythmia-
like activities. Myocardial tissue fibrosis has close interactions between the onset and 
Figure 5.5 siRNA transfection does not induce arrhythmia-like activity. (A–D) Comapring siRNA 
transfected condition with control condition on APD75 under fixed peak count (fixed beat rate). General 
population (>60%) of siGATA5, siPITX2, siKCNA5 transfected ACMs had prolonged APD75. siPLN 
tranfected group had shorter APD75. (E–H) The poulation distribution diagram of AI of the siRNA against 
GATA5, PITX2, KCNA5, PLN did not induce high AI populations. 
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persistence of AF [101]. To mimic certain aspects of tissue fibrosis, which could lead to 
the impair of conduction, human neonatal foreskin fibroblasts (1,000 cells/well of a 384-
well-plate) were added, 24 hours after the replate of ACMs (4,000 cells/well of a 384-well-
plate) [Figure 5.6A–C]. Physiological metrics were analyzed with single-cell action 
potential analysis. From the APD75 population distribution diagram and fixed peak count 
diagram, co-culturing ACM with fibroblasts prolongs the action potential duration [Figure 
5.7A, D]. However, it is not sufficient to induce arrhythmia-like activity [Figure 5.7G]. 
Next, to investigate the effect of adrenergic stimulation, isoproterenol and 
propranolol were acutely infused to the ACMs before the acquisition of the images. APD75 
population distribution and fixed peak count analysis confirmed the shortening of action 
potential duration when treated with 1 µM of isoproterenol along with significantly 
increased beat rate [Figure 5.7B–E]. Action potential duration was dramatically prolonged 
and correlating with the decrease of the beat rate in the 81 µM propranolol condition 
[Figure 5.7C–F]. In conclusion, first, co-culturing fibroblast with ACM prolongs the action 
potential duration. Also, the beat rate increased, and action potential duration was 
shortened under the effect of isoproterenol, while ACM treated with propranolol exhibit 
decrease of beat rate and prolonged action potential duration. Lastly, although the pro-
Figure 5.6 Co-culture fibroblasts with ACMs to mimic certain aspects of tissue fibrosis. (A) Schematic 
diagram of co-culturing fibroblasts with ACMs. (B) IF of pure ACMs (green) culture. (C) IF of ACMs (green) 
co-cultured with fibroblasts (red). 
  67 
arrhythmia effect of perturbagens is confirmed, no arrhythmia-like activity was detected in 
fibroblast co-culturing, nor the addition of isoproterenol and propranolol [Figure 5.7 H–I]. 
The key factors required for the inducing and maintaining of AF are substrates and 
abnormal stresses. Thus, we hypothesized that with the present of siRNA-mediated 
knockdown as the substrate, along with the conduction heterogeneity caused by co-
culturing ACM with fibroblasts, and under adrenergic stresses, could further induce 
Figure 5.7 Perturbagens including fibroblasts co-culture, β-adrenergic agonist–isoproterenol, and 
antagonist–propranolol, caused electrical remodeling but not sufficient to trigger arrhythmia-like activity. 
(A–F) Population distribution diagram of APD75 and fixed beat rate diagram showed the prolongation of 
action potential duration caused by co-culturing fibroblasts with ACM. APD75 were significantly shortened 
with the treatment of isproterenol, and were prolonged with the treatment of propranolol. (G–I) The poulation 
distribution diagram of AI of the 3 perturbagens treatment did not trigger arrhythmia-like activity. Fib: 
fibroblasts co-culture; Isop: isoproterenol 1 µM; Prop: propranolol 81 µM. 
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arrhythmia-like activity in ACMs. To test the hypothesis, siRNA was transfected while the 
ACMs were replated into the 384-well-plate, and 24 hours later, fibroblasts were mixed in 
the culture. After 2 days, cells were incubated with voltage-sensitive probes, 1 uM of 
isoproterenol or 81 uM of propranolol were added acutely before the image acquisition 
[Figure 5.8A]. 
Single-cell action potential data were analyzed in AI population distribution 
diagram. In the combinations of siRNA with one of the perturbagens, no arrhythmia-like 
activity was detected (data not shown). Moreover, AI was substantially escalated in the 
addition of fibroblasts along with propranolol in the siGATA5 transfected ACMs [Figure 
5.9A]. Interestingly, AI value remained low in the siGATA5-fibroblast-isoproterenol 
condition, indicating arrhythmogenic activity is triggered only through specific 
combinations of substrate and perturbagens. Compare to the action potential traces of the 
control condition, siGATA5 along with fibroblasts co-culture and propranolol treatment 
induces irregular contracting behavior and ectopic peaks during the beginning of 
repolarization [Figure 5.9B–C]. Similarly, a subpopulation of cells with large AI was 
observed in the siPITX2-fibroblast-propranolol combination, while lower AI value in the 
siPITX2-fibroblast-isoproterenol condition [Figure 5.9D]. The resulting arrhythmia-like  
Figure 5.8 Schematic diagram of transfecting siRNA, co-culturing fibroblasts, and the treatment of small 
compound perturbagens. 
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Figure 5.9 Specific combinations of AF-associated genes with perturbagens induced distinct arrhythmia-like 
activity. (A) Combination of siGATA5 with fibroblasts co-culture and propranolol induced high AI 
subpopulation. (B) Action potential trace of control ACM presented regular beating activity. (C) Action 
potential trace of siGATA5 with fibroblasts co-culture and propranolol showed premature ectopic peaks 
during the beginning of repolarization. (D) Combination of siPITX2 with fibroblasts co-culture and 
propranolol induced high AI subpopulation. (E) Action potential trace of siPITX2 with fibroblasts co-culture 
and propranolol showed extremely prolonged duration and EADs. (F) Combination of siKCNA5 with 
fibroblasts co-culture and isoproterenol induced high AI subpopulation. (G) Action potential trace of 
siKCNA5 with fibroblasts co-culture and isoproterenol had chaotic beating behavior with multiple double-
peak events. (H) Cells with high AI from different combinations plotted on APD75 vs peak count diagram 
showed clusters of distinct AF-associated genes and perturbagens combinations. Fib: fibroblasts co-culture; 
Isop: isoproterenol 1 µM; Prop: propranolol 81 µM. 
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activity occurs due to series of dramatically extended action potential duration and 
profound EADs [Figure 5.9E]. siKCNA5-fibroblast-isoproterenol also generates a 
subpopulation with extreme high AI value, whereas siKCNA-fibroblasts-propranolol 
condition exhibit less AI value [Figure 5.9F]. Multiple double-peaks were observed in the 
action potential trace, where it also showed severe chaotic beating activity [Figure 5.9G]. 
Distinct types of arrhythmic behaviors were induced by different combinations of substrate 
and perturbagens [Figure 5.9H], which correlated with clinical findings indicating 
distinctive mechanisms that lead to various subtypes of AF. In summary, the arrhythmic 
behavior could be induced by specific combinations of substrate and perturbagens. 
Different sets of substrate-perturbagen combination also produced distinct forms of 
arrhythmia-like activities. 
 
5.3 Discussion 
5.3.1 Single-cell analysis is a novel method to identify cardiac rhythm regulators 
and potential antiarrhythmic therapeutic targets. 
In the previous discussion, several advantages have been mentioned in functional 
assessment of cardiomyocytes.  To fully utilize the platform for identifying cardiac rhythm 
regulators and potential antiarrhythmic therapeutic targets, the single-cell analysis provides 
in-depth information both in macroscopic, the deviation of entire cellular population 
behavior after the treatment, and microscopic views, where subpopulations segregated 
through conditions ex. fixed beat rate or local contracting clusters. 
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The single-cell analysis enables a general view of population distributions on all 
three major parameters that determine the arrhythmia-like activities of the examined ACM: 
beat rate, APD75, and arrhythmia index (AI). Calculation of the mean values of these 
parameters directly across the cellular population with arrhythmia-like activity would 
generate unstable results with large standard deviation. These deviations were mainly 
contributed by subpopulations within the entire group. Heterogeneity within the culture is 
often observed, where subpopulations that have more severe phenotypes and others less, 
which reflects the heterogeneity of gene expressions mentioned in chapter 3 [85, 86]. By 
analyzing cellular arrhythmia-like behavior in single-cell level, the system could 
distinguish deviation and subpopulations from the bulk, which would be overlooked 
entirely via averaging the result of every cell, or applying classic whole-well analysis. 
Furthermore, the segregation of the subpopulation generates with single-cell analysis, 
produce meaningful results with statistical significance.  Conversely, the averaging 
strategy generates inconclusive results with low statistical power and large standard 
deviation.  
The beat rate of the cardiomyocyte and action potential duration are highly 
correlated, the higher beat rate is often paired with shorter action potential duration. Thus, 
distinguishing the prolongation or shortening of action potential duration should also 
consider the beat rate. Classic patch-clamp electrophysiology measures action potential 
duration difference through regulating and fixing the beat rate of the cell via 
electrostimulations. Similarly, the single-cell analysis could also cross-reference the 
parameters such as APD75 and AI by in silico fixing the beat rate. Simply categorize cells 
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with defined beat rate, the effect of the treatment which leads to the action potential 
duration difference could then be recognized. 
Lastly, being able to segregate the analysis in single-cell level, made selectively 
filtering cellular responses in a mixed-culture condition possible. The mixed-culture 
condition, either unintentionally, such as heterogeneity during differentiation, or 
intentionally, for example, the co-culture of CM sub-types or CM with fibroblasts, causes 
difficulties in the whole-well analysis due to the asynchronous contracting event. 
Moreover, the arrhythmia-like activity also induces asynchronous contracting event in sub-
clusters of cells. Segregation of cellular event into single-cell overcomes the problem 
which made detecting arrhythmia-like activity possible. In summary, the single-cell 
analysis provides macroscopic and microscopic aspects of evaluating functional results of 
cardiomyocytes that enable subpopulation analysis, in silico beat rate fixing for APD cross-
reference, and segregating mix-population results.  
 
5.3.2 siRNA-mediated knockdown of AF-associated genes induce abnormal action 
potential duration in ACM 
Ectopic beats that induce arrhythmia and atrial fibrillation are caused by susceptible 
substrate and perturbagens. Single-cell action potential analysis results showed that the 
siRNA-mediated down-regulation of the 4 previously known AF-associated genes – 
GATA5, KCNA5, and PITX2 – as well as fibroblast co-culture significantly prolong the 
action potential duration of ACM. Conversely, the down-regulation of PLN abbreviates the 
action potential duration. The dysregulation or mutation of GATA5, KCNA5, PITX2, and 
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PLN, as well as the fibrosis of the cardiac tissue, have been shown to act as substrates of 
AF. 
The family of GATA transcription factors regulates differentiation, growth, and 
survival of various cell types [102]. Within all 6 family members (GATA1-6), GATA4, 5, 
and 6 genes are explicitly expressed in mesoderm and endoderm-derived tissues [98, 103]. 
Functional overlapped with GATA4 and 6, GATA5 is a crucial transcription factor for 
proper cardiogenesis, particularly in the regulation of downstream GATA target gene 
expressions synergistically with NKX2-5 [104]. Evidence underscores several critical 
cardiac-specific genes with GATA binding elements such as sarcomeric genes, including 
myosin light chain-3 (MYL3), cardiac troponin C and I (TNNC1 and TNNI3). In addition, 
GATA family also regulates the expression of NCX, natriuretic peptide A and B (NPPA 
and NPPB), gap junction protein α 5 (GJA5), and Hand2 [105-110]. Lastly, multiple loss 
of function mutations of GATA5 have been identified in familial AF patients which points 
to the likely association of functionally impaired GATA5 with arrhythmia and AF [111, 
112]. The role during and after cardiac development suggesting the potential association of 
miss-regulation or functionally compromised GATA5 with AF. 
Previous studies have reported loss-of-function mutations in KCAN5 leads to 
decrease in IKur in lone AF patient [100, 113-115]. IKur is the major repolarizing current in 
human atrium and consistent with the result we have shown, the loss of IKur prolongs action 
potential duration as well as the effective refractory period (ERP) of the ACM, which 
increase the propensity for EADs [83, 116, 117]. Notably, the mutations of KCNA5 in lone 
AF patients is one of the few identified both in rare variant studies and GWAS analysis, 
indicating its vital link between AF. 
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PITX2, the paired-like homeodomain transcription factor, has a critical role during 
heart development (left-right asymmetry) and rhythm control [118, 119]. The adult-
specific Pitx2 deletion in mice causes significant electrical remodeling of the heart and 
develop AF [120]. Also, the promoter region of PITX2 contains TBX5-dependent cis-
regulatory elements (CREs), indicating TBX5, a transcription factor intensively involved 
in heart development, modulates PITX2 expression level. Moreover, studies have shown 
that PITX2 and TBX5 forms a TBX5-PITX2 incoherent feed-forward loop that regulates 
several atrial conduction genes and PITX2 along modulates the expression levels of several 
cardiac-specific genes such as HCN4, NPPA, and KCNQ1[120-122]. The dysregulation of 
PITX2 causes the onset of AF under triggers in mouse [122]. Markedly, PITX2 is the most 
significant and frequently reported AF-susceptibility locus in multiple GWAS studies 
[123-126]. Finally, 3 lost of function mutations have been identified in idiopathic AF 
patients, and all 3 mutations are located in homeodomain where amino acids are highly and 
even completely conserved among various species [127, 128]. Although the mechanisms 
of dysregulation or mutations of PITX2 lead to AF remains controversial, it is consistent 
that abnormality of PITX2 increases the susceptibility to AF [129].  
PLN act as a regulator protein of Ca2+ cycling and mediator of the adrenergic effect 
through the inhibition or activation of SERCA2a. Under dephosphorylated normal state, 
PLN interacts and decreases the Ca2+ affinity of SERCA2a, which leads to the decrease of 
Ca2+ cycling and reduced cardiac output. Upon phosphorylation, the inhibition of 
SERCA2a is terminated, Ca2+ affinity is raised, and cardiac output is then increased. 
Concurred with our findings, siRNA-mediated downregulation of PLN greatly shortens the 
action potential duration of ACM. Although no PLN mutation identified in lone AF 
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patients, numerous mutations in PLN have been reported associated with cardiac rhythm 
abnormalities and tachycardia. Most of the patients with PLN mutation have long clinical 
histories of comorbid conditions including AF, ventricular tachycardia (VT), hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM), heart failure (HF), and sudden 
cardiac death (SCD) [130, 131]. PLN heterozygote super-inhibition mutation in mouse 
exhibited high mortality at early stages (12 weeks postnatal), and Ca2+ uptake was 
dramatically inhibited [131, 132]. Whereas the hyperphosphorylation of PLN, which 
prevent the inhibition of SERCA2a, by excessive CaMKII activation induced AF in 
isolated human atrial myocytes [133, 134]. These data reveal the crucial role of PLN in 
Ca2+ cycling and rhythm control and correlates with our finds that the APD abbreviation 
of ACM is due to the siRNA-mediated down-regulation of PLN. 
In summary, our functional genomics approach using siRNA-mediated knock-
down results coincide with previous studies on the dysregulation of GATA5, KCAN5, 
PITX2, and PLN that leads to the predisposition of atrial arrhythmia. The conduction 
heterogeneity and abnormal action potential due to the co-culture of fibroblasts with ACM 
resonate with previously reported on structural remodeling induced AF. 
 
5.3.3 AF-associated perturbagens induce abnormal action potential duration in 
ACM 
Cardiac tissue fibrosis is a hallmark of pro-arrhythmogenic structural remodeling. 
As one of the most common features of AF, increased collagen deposition in lone-AF 
patients, as well as the positive correlation between extracellular matrix (ECM) volume 
with the persistence of AF [101, 135]. Atrial fibrosis results from a variety of cardiac insults 
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including but not limited to myocardial injuries due to infarction or surgeries, chronic heart 
failure, atrial dilation, or electrical abnormalities [136, 137]. Extensive research and 
experimental models have helped to elucidate the relationship between atrial fibrosis and 
AF [138, 139]. The conduction heterogeneity due to the structural remodeling leads to 
numerous local re-entry circuits that generate irregular rhythms or flutter activity [93, 140]. 
Thus, conduction abnormalities provide a basis for re-entry loop that shortens action 
potential duration or conduction delay that leads to the prolonging of action potential 
duration. Moreover, positive feedback model between electrical remodeling, structural 
remodeling, and AF is well established. Coincide with the ACM-fibroblasts co-culture 
result, a widely diffused population distribution was observed both in peak count and 
APD75. The increase of AI, as well as greater numbers of local circuits in the culture, 
indicates the conduction abnormalities and pro-arrhythmic effect of co-culturing 
fibroblasts with ACM. 
The isoproterenol challenge in AF patients and animal model with AF-associated 
substrates are arrhythmogenic [100, 141, 142]. Adrenergic stimulation has been shown to 
induce cytoplasmic Ca2+ load through various targets. The major targets of beta-adrenergic 
stimulation in the cardiomyocytes are the activation of L-type Ca2+ channels on the 
membrane; the activation of SR-located ryanodine receptors; phosphorylation of PLN 
which accelerates Ca2+ reuptake by the SR. These alternations induce faster CICR cycle 
thus increase stronger contraction and relaxation of the myofilament [143]. The 
cytoplasmic Ca2+ stress and the increase of beat rate act as perturbagens that induce 
arrhythmia-like behavior on ACM along with substances such as siGATA5 and siPITX2.  
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Propranolol is a non-selective beta-blocker with the affinity for both β 1 and 2 
adrenergic receptors. It has been widely used as rhythm control treatment for AF since its 
discovered in the 1960s. With opposite mechanism of Isoproterenol, Propranolol reduces 
Ca2+ cycling, thus, decrease the beat rate and prolongs action potential duration. The 
antiarrhythmic property of Propranolol is by reducing the event of re-entry circuit and the 
decrease of heart rate that leads to AF or atrial flutter. However, under the state of 
prolonged action potential duration, applying Propranolol further exacerbate the delay of 
the Ca2+ cycle, which could act as a trigger of EADs and induce arrhythmia. Interestingly, 
in long QT syndrome 3 clinical studies, prescribing high concentration of Propranolol also 
resulted in a proarrhythmic effect [144]. 
In summary, the functional assessment result indicating these known AF-associated 
perturbagens cause abnormal action potential duration, which in the present of AF-
substrate may further induce AF in patients or arrhythmia-like behavior in vitro. 
 
5.3.4 Induce Arrhythmia-like activity with AF-substrate and perturbagens 
The specific combination of arrhythmia substrate and the trigger could induce and 
sustain the arrhythmia behavior [142, 145, 146]. GATA5 down-regulation reduces the 
expression of contractile proteins, gap junction proteins, and several cardiac-specific 
proteins [109]. The addition of fibroblast in the culture further exacerbates the cell-cell 
coupling that leads to the heterogeneity of conduction. Under the Ca2+ handling stress 
induced by propranolol, action potential duration was abnormally extended, keeping the 
cell depolarized for more extended periods, thus, allowing the occurrence of EADs at phase 
2 [Fig]. PITX2 have been known for regulating Ca2+ homeostasis [120]. The reduced 
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expression of PITX2 via siRNA knockdown impairs Ca2+ handling ability of the 
cardiomyocyte. With the co-culture of fibroblasts, the propagation of electrical signals was 
then fragmented. Under the effect of propranolol, cytoplasmic Ca2+ stress surged by the 
reduction of CICR cycling rate. Action potential duration as well as ERP was markedly 
prolonged, which leads to incomplete repolarizations and promotes premature beats [Fig]. 
Lastly, KCNA5 down-regulation decreases IKur and prolongs action potential. Disrupting 
normal excitation rhythm by the activation of adrenergic-stimulation increases the 
susceptibility to arrhythmia-like activity in ACMs. Irregular peak-to-peak interval and 
reoccurring ectopic peaks were detected in the action potential of the siKCNA5-fibroblast-
isoproterenol condition. Consistent with our observations, the vulnerability to adrenergic 
stress observed due to compromised IKur have been described both in the murine model and 
AF patients with haploid KCNA5 loss-of-function mutation [100]. In conclusion, 
arrhythmic activities were observed in distinct combinations of electrical remodeling 
substrate and AF-associated perturbagens. Furthermore, differential molecular causes lead 
to diverse subtypes of arrhythmia-like phenotypes, reflecting the broad spectrum of AF 
mechanisms documented in the clinical data, and emphasizing the importance of targeting 
specific AF subtypes with particular anti-arrhythmic treatments. 
 
5.4 Conclusion 
To validate the platform, a list of siRNA against 20 previously known AF-
associated genes identified both through rare variant and GWAS were transfected to ACM. 
11 out of 20 siRNAs showed either prolong or shortening of the action potential duration, 
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however, none observed arrhythmia-like activity. Perturbagens that were commonly 
associated with AF, including the fibroblasts co-culture mimicking tissue fibrosis, 
isoproterenol and propranolol as β-adrenergic stimulation/inhibition, were then tested. 
Perturbagens also found inducing electrical remodeling, yet not arrhythmia-like activity. 
Since AF is often triggered in the presence of both substrate (miss-regulation of 
AF-associated genes) and perturbagens, we than transfected the siRNA and applied 
perturbagens at the same time. Severe arrhythmia-like activities were detected in 3 different 
combinations: 1. siGATA5 with fibroblasts co-culture and propranolol; 2. siPITX2 with 
fibroblasts co-culture and propranolol; 3. siKCNA5 with fibroblasts co-culture and 
isoproterenol. Moreover, different combinations of substrate and perturbagens presented 
distinct arrhythmia phenotypes, indicating the complexity of the disease and the needs to 
identify and then target the specific regulatory pathway that leads to arrhythmia. 
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Chapter 6  
 
Future work and Conclusion 
 
 
 
 
 
6.1 Future Work 
6.1.1 Recapitulate Arrhythmia-like Phenotype in Patient-specific Mutation ACMs 
Phenotypical assessments mentioned above were done by utilizing siRNA-
mediated knockdown of the expression of the genes. However, this loss-of-function 
experimental design does not fully recapitulate the disease mechanism of action. siRNA-
mediated knockdown could mimic certain aspects of the misregulation of the genes that 
occurs in the general AF population, whereas in familial AF, arrhythmias are caused by the 
mutation of the genes. Thus, being able to generate patient-specific mutation ACMs are 
essential for validating the gene candidate and the system itself. 
CRISPR-Cas9 gene editing technique is frequently used to generate specific point 
mutation lines. Single-strand guide RNA (sgRNA) was designed to induce a double strand 
break in the proximity of the desired point mutation base pair, and single-strand 
oligodeoxynucleotide (ssODN) acted as a repair template to facilitate homology-directed 
  81 
repair (HDR) mechanism instead of activating non-homologous end joining (NHEJ) 
mechanism. sgRNA, ssODN, along with Cas9 protein were then transfected into hPSCs 
via electroporation, colonies were isolated and sequenced. Lines with heterozygous 
mutation, homozygous mutation, and isogenic controls were then expanded and 
differentiated into day 25 ACMs. We are currently functionally evaluating the loss-of-
function mutation of KCAN5 p.E375X heterozygote (KCNA5E375X/+) and homozygote 
(KCNA5E375X/E375X) and the gain-of-function mutation of KCNA4 p.D322H heterozygote 
(KCNA5D322H/+) and homozygote (KCNA5D322H/D322H) [Figure 6.1A–B]. Meanwhile also 
generating various lines including lost-of function mutation GATA5 p.W200G, and loss-
of-function mutation of PITX2c p.R122C. 
siRNA-mediated knockdown functional screening platform provides tremendous 
throughput for primary and secondary (validation) assays. CRISPR-Cas patient-specific 
mutation technique could then further validate the resulting candidates and elucidate 
detailed disease mechanism of action. 
 
Figure 6.1 Generation of KCNA5 AF patient-specific lost-of-function mutation with CRISPR-Cas gene 
editing technique. (A) Sequence chromatogram of normal (wild type) KCNA5 vs. KCNA5 patient-specific 
lost-of-function mutation p.E375X heterozygote. (B) Schematic diagram of KCNA5 protein structure. 
E375X mutation truncates half of the structure including the voltage sensing domain and the pore domain. 
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6.1.2 Large-scale phenotypical screens across the genome 
Maintaining the throughput and without sacrificing the readout resolution is the 
most considerabel advantages of the system. We currently are conducting a large-scale 
screen focusing on the “druggable” library and candidates that play essential roles in 
regulating CM physiology. The list of siRNA candidates (4239) includes G-protein 
receptors, kinases, phosphatases, transcription factors, epigenetic regulators, ubiquitins, 
and atrial differentially-expressed transcripts. All of the candidates were screened in both 
baseline condition and under β-adrenergic stress. Readouts were based on APD75 to 
evaluate the effect of electrical remodeling on prolonging or shortening the action potential 
duration, as well as through AI to assess the degree of arrhythmia-like activities [Figure 
6.2A–B]. 
Throughout the large-scale phenotypical screens, we will identify novel cardiac 
rhythm regulators and potential arrhythmia-causing genes. Once the candidates are 
validated and confirmed, we are planning to conduct sensitized screen on small compounds 
Figure 6.2 Large-scale phenotypical screens with the high-throughput single-cell functional screening 
platform. (A) Total 4239 candidates screened. The result plotted in the order of the length of APD75. (B) The 
screening result plotted in APD75 vs.. normalized AI. 
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by transfecting siRNA against these candidate genes to explore potential anti-arrhythmic 
treatments. 
6.1.3 Functional genomics as novel anti-arrhythmic treatments 
According to the experimental result in 5.3.2, several siRNA against previously 
known AF-associated genes prolongs the action potential duration, including siGATA5. 
On the contrary, siPLN and other candidates shorten the action potential duration [Figure 
6.3A–B]. Thus, by co-transfecting siGATA5 and siPLN, the resulting action potential 
duration was situated between the duration of the single transfection of siGATA5 and 
siPLN. The result indicates abnormal action potential duration can potentially be reverted 
to normal by inducing a “functionally antagonist” [Figure 6.3C]. Moreover, siRNAs and 
small compounds that inhibit target gene function may also be potential antiarrhythmics. 
 
6.2 Conclusion 
This thesis summarized an original system that utilizes hPSC-derived ACM on a 
high-throughput single-cell phenotypical screening platform to identify novel AF-
associated genes. 
Figure 6.3 Applying functional genomics to identify novel anti-arrhythmics. (A) Transfection of siGATA5 
prolongs the action potential duration of ACM. (B) Transfection of siPLN shortens the action potential 
duration. (C) Co-transfect both siGATA5 and siPLN revert the phenotype and normalized the action potential 
duration. 
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Genome-wide microarray screen identified Id1 is required and sufficient to 
differentiate MCPs from hPSCs. Gene regulatory network of MCP reveals Id1’s role in the 
early mesoderm specification stage. Id1 activates the expression of mesoderm genes KDR 
and MESP1, as well as suppressing endoderm genes such as FOXA2. Furthermore, in vivo 
studies revealed the overexpression of Id1 enlarges mesoderm formation and followed by 
larger cardiac tissue in Xenopus. Also, from the Id-quadruple knockout mouse embryo 
mutant, we confirmed Id gene family is required during mammalian early heart formation. 
Thus, we have established a highly efficient cardiogenic mesoderm differentiation protocol 
to generate large-scales of CM for the study of cardiac physiology, regeneration medicine, 
cell-based therapy, disease modeling, and drug discovery. 
Atrial fibrillation is an arrhythmia occurs only in the atrium, to further study and 
model AF, ACM is required. Applying retinoic acid as a pro-atrial differentiation cue on 
day 5 CMP generates highly homogenous ACMs. ACM s were than molecularly validated 
through RNA-seq, and functionally validated with: 1. action potential; 2. calcium handling; 
3. contractility; 4. atrial-specific compound 4-aminopyridine. 
To efficiently screen through large-scale libraries to identify novel AF-associated 
genes, we established a fully automated high-throughput and single-cell functional 
screening platform. ACMs were replated into 384-well-plate and incubated with voltage-
sensitive probe via a liquid handler.  Cells were then recorded under high-speed microscopy 
and analyzed by image processing software. The analysis algorithm generated single cell 
action potential traces and retrieved physiological metrics. To evaluate the degree of 
arrhythmia-like activity, APD75 and AI value were plotted against cell population.  
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Lastly, siRNA of 20 previous know AF-associated genes were transfected 
individually to validate the system. According to the result, a few leads to the electrical 
remodeling (prolongation or shortening of APD) of ACM, yet not sufficient to induce 
arrhythmia-like activity. Furthermore, along with distinct combinations of perturbagens 
(fibroblasts co-culture, isoproterenol, propranolol), these siRNA induced distinct 
arrhythmia-like-activity. The result indicates the different mechanism of actions could lead 
to distinct arrhythmia phenotypes, and require specific anti-arrhythmic treatments. Thus, 
the prerequisite of developing phenotype-specific antiarrhythmics is to identify novel 
cardiac rhythm regulators and AF-causing genes. This original high-throughput functional 
screening platform enables single-cell resolution large-scale arrhythmia-like phenotypical 
screens to identify novel AF-causing candidates. 
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